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Rolling circle amplification (RCA)-based DNA nanotechnologies have 
attracted tremendous interest to develop new platform of drug delivery. First, DNA 
nanoballs with antisense oligonucleotide (ASO)-complementary sequences could 
provide sequence-specific loading of dual ASOs, Dz13 and OGX-427, and coating 
with hyaluronic acid (HA) promoted CD44 receptor-mediated delivery of ASOs to 
tumor cells. Importantly, ASOs delivered by HA-coated DNA nanoballs silenced 
the expression of their target mRNAs of ASO, exerting potent anticancer effects in 
vitro and in vivo. Second, DNA polyaptamer nanothreads of protein tyrosine 
kinase 7 (PTK7) receptor were synthesized by RCA. To enhance the anchoring 
capability of polyaptamers onto reduced graphene oxide (rGO), oligonucleotide 
bridge sequence between repeating aptamer sequences was introduced. Surface 
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modification of rGO with DNA polyaptamer nanothreads (PNTrGO) resulted in 
improved cellular uptake into PTK7-positive tumor cell lines and enhanced tumor 
tissue accumulation compared to oligoT-bridged scrambled polyaptamer-anchored 
rGO nanosheets. Moreover, systemic administration of doxorubicin using PNTrGO 
enhanced the antitumor effects in mice bearing PTK7-positive tumors. Third, an 
injectable hydrogel based on drug-specific DNA polyaptamer networks was 
developed by using graphene oxide (GO) nanosheets as a crosslinker. Graphene 
oxide-crosslinked DNA polyaptamer (GO-PA) hybrid hydrogels were constructed 
by running single step RCA of DNA template in the presence of GO nanosheet. 
GO-PA hybrid hydrogel showed drug-specificity towards kanamycin. The drug 
loading efficiency of GO-PA was 58.0 % for kanamycin, but 1.2% for gentamicin. 
 
Keywords: DNA nanostructures, rolling circle amplification, drug delivery, 
aptamer, graphene oxide, reduced graphene oxide 
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Rolling circle amplification (RCA) is an isothermal, enzymatic process mediated 
by unique DNA and RNA polymerases (π29, Bst, and Vent exo-DNA polymerase for 
DNA, and T7 RNA polymerase for RNA) to generate long single stranded DNA 
(ssDNA) and RNA [1]. In a typical RCA reaction, the polymerase continuously adds 
nucleotides (nt) to the primer annealed to a circular template, resulting in replicating 
the circular template hundreds to thousands of times (Fig. I-1). Therefore, the end 
products of an RCA reaction are extremely long ssDNA molecules (usually hundreds 
of thousands of nucleotides and between hundreds of nanometers and microns in 
length) with tandem repeat units that are complementary to the circular DNA 
template.  
As a method for molecular amplification, RCA has several attractive features. 
Unlike the polymerase chain reaction, which requires a thermal cycler and 
thermostable DNA polymerase, RCA utilizes the isothermal nature of π29 DNA 
polymerase, which catalyzes DNA polymerization at a constant temperature (at 30°C 
or even room temperature) [2]. Therefore, neither thermally stable DNA polymerase 
nor sophisticated instrumentation is required. In addition, RCA-based assays offer 
both high sensitivity and high specificity. As a method for signal amplification 
through either linear amplification or exponential growth, RCA typically provides an 
approximately 1,000-fold (for linear amplification) to 10,000-fold increase in the 
intensity of the signal [3]. Since RCA reaction can only be initiated after specific 























an RCA-based assay is highly specific [4]. Furthermore, by designing the circular 
DNA templates and primers, the length, sequence, composition, structure, and 
rigidity of the RCA product can be finely tuned [5]. Collectively, efficient isothermal 
amplification, single molecule sensitivity/selectivity, structural and compositional 
versatility, and multivalency make RCA a powerful tool in biomedical and 
nanotechnology fields. 
RCA has traditionally been used for ultrasensitive detection methods of DNA [6], 
RNA [7], DNA methylation [8], small molecules [9], proteins [10], and cells [11] in 
areas of diagnostic genomics and proteomics. More recently, RCA has also attracted 
significant attention for its use in generating DNA nanostructures such as origami 
[12], nanotubes [13], DNA nanoscaffolds [14] for periodic nanoassembly, and DNA 
large-scale (micro- or macroscale) materials [15]. Furthermore, RCA has been used 
for amplifying functional sequences including DNA aptamers [16], DNAzymes [17], 
and restriction enzyme sites [18]. These functional RCA-based nanotechnologies 












2. Biomedical applications of RCA-based nanotechnologies 
RCA has currently been used for biomedical applications such as target cancer cell 
recognition, bioimaing, and biosensor, as listed in Table I-1. 
2.1. Target cancer cell recognition 
The development of a method for accurate, sensitive, selective, and rapid 
recognition and quantitation of cancer cells is important for the early diagnosis, 
treatment, and mechanistic studies [19]. Currently, there are conventional 
technologies for capture and isolation of cancer cells including the polymerase 
chain reaction, immunohistochemistry, and flow cytometry [20]. However, some of 
those methods require relatively complicated, time-consuming and inefficient 
methods, while others still have unsatisfactory sensitivity and specificity. To 
overcome these problems, RCA method have recently been investigated and 
developed to enhance the efficiency of signal amplification [21].  
Sheng et al. developed a platform approach to recognize target cancer cells 
using RCA-directed enzyme-catalyzed polymerization [22]. To detect human 
breast cancer MCF-7 cells, a hairpin-structured aptamer with a strong binding 
affinity and selectivity to protein receptor was used. In the presence of the target 
cancer cell, RCA reaction can trigger enzymatically catalyzed polymerization by 
releasing cancer cells form electrode surface. For sensitive and selective 
recognition of Ramos cancer cells, bio-bar-code nanoprobe-based RCA 




Table I-1. RCA-based nucleic acid nanotechnologies for biomedical 
applications 
 
Application Conjugation Functional domain Reference 
Target cancer  
cell recognition 
Thiol-C6 SYL3C aptamer [22] 
AuNP TD05, TE02 aptamer [23] 
Polystyrene 
microspheres 
TD05 aptamer [24] 
Biotin Sgc8 aptamer [25] 
Bioimaging 
Protein matrix miR-222 [32] 





- Neuraminidase viral RNA [35] 
- Target mRNA [36] 
Biosensor 
- Pyrophosphate [38] 
Antibody SYBR/DNA conjugate [39] 
- Deoxyribozyme [40] 





recognition of cancer cells. Amplified signals were measured by observing the 
chemiluminescence intensity change [23]. The RCA technique was combined with 
oligonucleotide functionalized nanoparticles, and the signal amplification systems 
exhibited high sensitivity and specificity with the detection limits of 10 Ramos 
cells ml-1 [24]. Zhao et al. developed multivalent DNA network for recognition and 
release of cancer cells. The DNA network was synthesized by RCA, and comprised 
of repeating adhesive aptamer domain [25].  
 
2.2. Bioimaging 
The ability of visualizing targeted biomolecules at the single-cell level is 
essential for understanding the biological roles of biomolecules and diagnosing 
diseases [26]. To achieve ultrasensitive visualization of biomolecules, the probes to 
selectively bind and label the biomolecules were widely used. Although probes 
conjugated with nanostructure reporters such as metallic nanoparticles [27], 
quantum dots [28], nanocrystals [29], and nanodiamonds [30] have been developed 
to improve signal-to-noise ratio, these solid-core labels tend to aggregate and form 
nonspecific bindings with surfaces and other molecules [31]. To overcome the 
challenging barriers for single molecule probes, RCA has been well studied and 
used in bioimaging.   
A study reported that target-primed RCA method can visualize miRNA 
expression patterns at the single-cell level with high sensitivity and selectivity [32]. 
After hybridization with fluorescent detection probes, target miRNA molecules can 
be visualized with ultrahigh sensitivity. For investigation of systematic cell 
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signaling, a proximity ligation technique was combined with RCA [33]. In cases 
where two differently labeled secondary antibodies are in close proximity, the 
oligonucleotide sequences can be amplified by means of RCA. This product is 
easily detected through hybridization of complementary fluorescence-labeled 
oligonucleotides. Chen’s group developed polymeric sequence probe which was 
prepared by RCA [34, 35]. Since polymeric sequence probe has ~2000 tandem 
repeat target-binding sequences and label-binding sequences, it provided higher 
specific binding rates and strong fluorescence signal and single molecules such as 
DNA of Mycobacterium tuberculosis and viral RNA of influenza A can be clearly 
detected. In addition, Larsson et al. demonstrated that RCA technique was used for 
visualization of individual mRNA molecules [36]. 
 
2.3. Biosensor 
RCA can amplify a single molecular binding event over a thousand fold, 
making it ideal for biosensing assay. The isothermal nature of RCA provides new 
possibilities for point-of-care diagnostics compared to other techniques such as 
PCR and enzyme-linked immunosorbent assay that use sophisticated and 
expensive instruments [37]. Due to these attractive features, RCA has been a 
promising analytical method for the detections of nucleic acids as well as other 
biomolecules, including protein, RNA, pathogen, and small molecules.  
Mashimo et al. demonstrated that a bioluminescence assay combined with RCA 
can be used for quantitative analysis of miRNA [38]. The sensor was capable of 
detecting specifically as low as 0.1 fmol of a target small RNA within a total RNA 
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extract with high reproducibility. Cascade fluorescent DNA nanotags can be 
utilized for sensitive protein detection using streptavidin conjugated antibodies that 
carry multiple RCA primers [39]. For detection of small molecule such as 
guanosine triphosphate, Li and co-workers have applied a strategy to convert a 
kinase DNAzyme into RCA-based sensor [40]. A surface plasmon resonance DNA 
biosensor based on RCA with a gold nanoparticle surface was developed for 



















3. RCA-based nucleic acid nanostructures for drug delivery 
RCA has been used for amplifying functional sequences including DNA aptamers, 
DNAzymes, and restriction enzyme sites. These functional RCA-based 
nanotechnologies have been utilized for drug delivery, as listed in Table I-2. 
3.1. Nucleic acid drug delivery 
Assembly of DNA nanoribbon structures with RCA have recently been 
developed for delivery of CpG oligonucleotide (ODN) [42, 43]. To prepare various 
types of DNA nanoribbon structures with RCA product, the researchers used 
various short staple oligonucleotides. In this study, they demonstrated that their 16 
nm DNA origami nanoribbons showed more efficient cellular uptake and improved 
the release of TNF-α from RAW264.7 cells than single ss- or dsDNA, suggesting 
that these nanoribbons are resistant to nuclease degradation.  
Long ssRNA produced by RCA using T7 RNA polymerase instead of π29 
DNA polymerase had been designed for RNA-DNA hybrid nanowires [44]. 
Various types of RNA-DNA hybrid origami nanostructures were prepared using 
different kinds of staple short DNAs. The RNA-DNA hybrid nanowires have 
potential in delivery of small interfering RNA (siRNA). 
Y-shaped DNA nanostructures self-assembled were prepared by RCA 
following to site-specific restriction cleavage [45]. The Y-shaped DNA 
nanostructures had a three-way junction in a core and three hairpin loops in arms 
which hybridized with folic acid conjugated siRNA containing its complementary 
overhangs. These Y-shaped DNA nanostructures hybridized with folic acid 







Table I-2. Drug delivery systems based on RCA nanotechnology 
 
Drug Nanostructure Composition Reference 
CpG ODN Nanoribbon Staple DNA strand [42, 43] 
siRNA Nanowire RNA-DNA hybrid [44] 
siRNA Y-shaped DNA Folic acid [45] 
siRNA  RNA microsponge PEI [46] 
ASO DNA microsponge PEI, PLL [47] 
Dox Linear poly-aptamer Drug loading strand [48] 
Dox DNA nanoflower Multicolor molecules [49, 50] 
Dox DNA nanoclew DNase I, folic acid [51] 
Dox DNA origami 
AuNP, CPP,  








GFP showed higher gene silencing effect compared to folic acid modified siRNA 
alone when they were treated to GFP-KB cells.  
Hammond’s group developed self-assembled RNA microsponges for siRNA 
delivery [46]. The RNA microsponges were synthesized by RNA technique and 
contained antisense and sense sequences of siRNA. These RNA microsponges 
were condensed by mixing with a synthetic cationic polymer, polyethylenimine 
(PEI), for increase of transfection efficiency. Moreover, antisense oligonucleotides 
were also delivered via the spherical microsponges [47]. Here, the RCA products 
were long ssDNA which contained antisense ODN. The antisense ODN 
microsponges were condensed via complexation with poly-L-lysine (PLL) which is 
synthetic cationic polymer. The ODN particles were coated with short ssDNA 
through electrostatic interactions. Finally, PEI was added to the ODN/PLL/ssDNA 
particles to generate layer-by-layer ODN nanoparticles for efficient delivery of 
antisense ODN. 
3.2. Small molecule drug delivery 
The RCA products have been used not only for nucleic acid drug delivery, but 
also for chemical drug delivery. A polyvalent aptamer system delivered an 
anticancer drug, doxorubicin (Dox), in a targeted delivery manner [48]. They used 
the property of Dox which can be intercalated to ssDNA for loading the drug to 
RCA product. The spacer region between one aptamer and another aptamer was 
hybridized its complementary strand for Dox loading. The polyvalent aptamer 
delivered the anticancer agent to protein tyrosine kinase 7 (PTK7), which binds to 
the aptamer, overexpressing cells. Similar approaches with DNA nanostructures 
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called “DNA nanoflowers” were developed for targeted drug delivery [49, 50]. 
They designed the template sequences for RCA including anti-PTK7 aptamer and 
drug loading sites. These DNA nanoflowers were used both for Dox delivery and 
cellular imaging by using fluorescent dye conjugated dUTP during RCA reaction.  
The self-degradable DNA nanostructures in low pH environment were prepared 
by combining RCA products capable to load anticancer drug, Dox, and 
acid-responsive polymeric nanocapsules including DNase I [51]. DNase I was 
incorporated into the positively charged thin polymeric shells that was cross-linked 
by acid-degradable cross-linkers. To achieve active tumor targeting delivery of 
anticancer drug, folic acid was conjugated with DNA oligomer which was 
complementary to the DNA nanoclews. The study demonstrated that Dox could be 
released from their DNA nanoclews which had been taken up by MCF-7 cells via 
receptor mediated endocytosis because the DNase I was activated due to the low 
pH of endosomes.  
The DNA origami structures produced by RCA with three staple strands also 
have been used to decorate on gold nanoparticles [52]. The DNA origami, which 
was about 16 nm in width and several hundred nanometers in length, let the 
nanoparticles be able to carry Dox for anticancer therapy or quantum dot for 
cellular imaging. Cell-penetrating peptides (CPP) were introduced to the DNA 
origami structures via electrostatic interactions to enhance the cellular uptake of 
the nanoparticles. A few drug delivery systems have been produced by RCA so far, 




4. Scope of the studies 
 
For biomedical applications, DNA nanomaterials have attracted tremendous 
interest, owing to the typical biocompatibility and biodegradability. In particular, 
the DNA amplification technique, RCA, can produce a long single stranded DNA 
using a circular DNA template and special DNA polymerase. Since RCA products 
can be tailor-designed by manipulating the circular template, RCA has been 
employed to generate complex DNA nanostructures and functional sequences. All 
these properties make multifunctional DNA nanostructures promising for versatile 
biomedical applications. As a proof-of-principle demonstration, in this study, DNA 
nanostructures were integrated with antisense oligonucleotides (ASOs), DNA 
aptamers, and drug loading sites, and the resultant functional DNA nanostructures 
were used to explore new approaches for drug delivery (Fig. I-2). 
In chapter II, we designed biomimetic DNA nanoballs for delivery of multiple 
ASOs. Hyaluronic acid (HA)-coated, Mu peptide-condensed, dual ASO-loaded 
DNA nanoballs (HMA nanoballs) showed considerable cellular entry of 
Cy5-incorporated RCA product DNA and fluorescent ASOs. Dual ASOs, Dz13 and 
OGX-427, delivered by HMA nanoballs could reduce the levels of protein targets 
and exert anticancer effects.  
In chapter III, we reported reduced graphene oxide nanosheets anchoring 
receptor-specific polyaptamer nanothreads (PNTrGO) for targeted drug delivery. 
PTK7 polyaptamer nanothreads with 22-mer oligoT bridges showed higher 























overexpressing PTK7, the uptake of PNTrGO was 2.1-fold higher than that of 
oligoT-bridged scrambled polyaptamer-anchored rGO after 15 min pulse.  
In chapter IV, we developed an injectable hydrogel based on drug-specific 
DNA polyaptamer networks using graphene oxide nanosheets as a crosslinker. 
Graphene oxide-crosslinked DNA polyaptamer (GO-PA) hybrid hydrogels 
revealed bird nest-like surface morphology, 700 % of swelling ratios in 2 hr, and 
viscoelasticity suitable for injection and retention. GO-PA hybrid hydrogel showed 
drug-specificity towards kanamycin and the drug loading efficiency of GO-PA was 
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Chapter II  
 



















Recently, functional oligonucleotides have been studied as a major class of 
nucleic acid-based therapeutics [1]. Antisense oligonucleotides (ASOs) and micro 
RNA are examples of oligonucleotides with therapeutic potentials. However, these 
oligonucleotides suffer from drawbacks, such as instability against nucleases and 
limited cellular uptake owing to their high negative charges. To overcome these 
drawbacks, researchers delivered oligonucleotides using cationic lipids or 
polymer-based delivery systems. Cationic nanoparticles have previously been used 
to deliver single stranded oligonucleotides based on charge-charge loading to 
cationic liposomes [2,3] and polymer-based nanoparticles [4,5]. However, the 
cationic nanoparticle-associated cytotoxicity [6] requires the development of other 
carriers not cationic as well as biomimetic for delivery of oligonucleotides.   
Rolling circle amplification (RCA) is an enzymatic process that produces a 
single-stranded DNA (ssDNA) from a circular template. The resulting ssDNA is 
composed of complementary-sequence repeats of the circular template. RCA 
technology was originally used for DNA detection in genomics; however, 
additional applications using RCA have been reported [7]. Recently, RCA was 
applied to construct DNA nanostructures and DNA hydrogels [8-11]. 
In this study, we used RCA-amplified DNA to produce an oligonucleotide 
delivery system. As model oligonucleotides, we chose two ASO oligonucleotides. 
To load ASO to the delivery system, we used sequence-specific hybridization 
rather than cationic nanoparticle-based charge-charge interaction. The template for 
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RCA was designed to have complementary sequences for two different ASOs and 
to produce poly-binding sites for ASOs upon RCA amplification. Exploiting the 
DNA condensation mechanisms of viruses, we employed cationic Mu peptides 
derived from the adenovirus core complex to condense ASO-hybridized RCA 
products (ARP) and produce DNA nanoballs. The surface of ASO-loaded DNA 
nanoballs was coated with hyaluronic acid (HA), a ligand for CD44 receptors 
overexpressed by tumor cells [12], for tumor-targeted delivery.  
Here, we demonstrated that DNA nanoballs with ASO-complementary 
sequences could provide sequence-specific loading of dual ASOs, and coating with 
HA promoted CD44 receptor-mediated delivery of ASOs to tumor cells. 
Importantly, ASOs delivered by HA-coated DNA nanoballs silenced the 
expression of their target mRNAs of ASO, exerting potent anticancer effects in 











2. Materials and methods 
 
2.1. Construction of ASO-hybridized DNA nanoballs  
ASO-hybridized DNA nanoballs were constructed by (1) amplifying ssDNA 
containing ASO-binding sites by RCA, (2) hybridizing with ASO, and (3) 
condensing with cationic Mu peptides. In the first step, an RCA template for 
complementary binding with ASOs was circularized using primers. Briefly, 0.5 µM 
of 5’-phosphorylated linear ssDNA template and primer (Macrogen Inc., Daejeon, 
Republic of Korea) were annealed in hybridization buffer (10 mM Tris-HCl, 1 mM 
EDTA, 100 mM NaCl, pH 8.0) and mixed with T4 DNA ligase (125 units/mL) 
(Thermo Scientific, Waltham, MA, USA) to close the nick in the circular RCA 
template. After inactivating T4 DNA ligase by heating to 70°C, the circular RCA 
template (200 µL) was incubated at 30°C for 12 h with π29 DNA polymerase (100 
units/mL) (Thermo Scientific) and 2 mM dNTPs (Intron Biotechnology Inc., Seoul, 
Republic of Korea). In some experiments, fluorescent RCA products were prepared 
by adding 25 µM of Cy5-dCTP to 2 mM dNTPs during the RCA reaction. After 
heat-inactivating π29 DNA polymerase at 70°C for 10 min, residual dNTPs were 
removed by centrifugation at 13,000 rpm for 10 min. The resulting pellet of RCA 
product was resuspended in water, and its concentration was measured using a 
Nanodrop spectrophotometer (Thermo Scientific). Two different ASOs—Dz13 
(125 µg) and OGX-427 (125 µg)—were hybridized with 1 mL of RCA products 
(500 µg DNA/mL) by heating at 95°C for 10 min and then cooling gradually at 
room temperature. The cationic Mu peptide (Peptron, Daejeon, Republic of Korea) 
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was added to the resulting dual ARP at a weight ratio of 1:1 to form a nanoball-like 
structure. The resulting complexes of Mu-condensed, dual ASO-hybridized DNA 
nanoballs (MA nanoballs) were mixed with 214 kDa HA (Lifecore Biomedical Inc., 
Chaska, MN, USA) at a DNA:Mu:HA weight ratio of 1:1:5. HA-coated, 
Mu-condensed, dual ASO-hybridized DNA nanoballs (HMA nanoballs) were 
stored at 4°C until use. In some experiments, RCA products alone were mixed with 
Mu peptide at a weight ratio of 1:1, and coated with HA at a DNA:Mu:HA ratio of 
1:1:5 to produce HA-coated, Mu-condensed DNA nanoballs without ASOs (HM 
nanoballs). 
 
2.2. Quantification of hybridized ASOs 
The two ASOs, Dz13 and OGX-427, were labeled using different fluorescent 
dyes to measure the efficiency of hybridization to RCA products. Fluorescein 
(FAM)-conjugated Dz13 and 6-carboxy-x-rhodamine (ROX)-tagged OGX-427 
were supplied by Bioneer Corporation (Daejeon, Republic of Korea). The 
fluorescent dye-modified ASOs, FAM-Dz13 and ROX-OGX-427 (5.5 µg each), 
were hybridized with 100 µL of RCA products (200 µg DNA/mL). The procedure 
described in section 2.1 was adopted for loading fluorescent dye-modified ASOs to 
RCA products. Unloaded fluorescent ASOs were removed by repeated 
centrifugation at 13,000 rpm for 10 min, and the fluorescence intensity of the 
supernatants was measured using a Spectramax Gemini XS microplate fluorometer 
(Molecular Devices Cooperation, Sunnyvale, CA, USA). The amounts of 
hybridized Dz13 and OGX-427 were calculated from calibration curves of 
31 
 
fluorescence intensity of each fluorescent dye-labeled ASO as a function of 
concentration.  
 
2.3. Characterization study of DNA nanoballs   
The sizes of various DNA nanoballs, with or without Mu peptide-induced 
condensation and HA coating, were measured by dynamic light scattering. The zeta 
potentials of DNA nanoballs were also measured by laser Doppler 
microelectrophoresis at an angle of 22° using an ELSZ-1000 instrument (Photal, 
Osaka, Japan). The morphology of DNA nanoballs was visualized by scanning 
electron microscopy (SEM) using a Supra 55VP system (Carl Zeiss, Oberkochen, 
Germany). The stability of ARP, MA nanoballs, and HMA nanoballs against 
nucleases was tested by incubating 1 µg of DNA with 1 unit of DNase I (Sigma, St. 
Louis, MO, USA) at 37°C for 30 min. The mixture was electrophoresed on 1% 
agarose gels and visualized by staining with Safe-Pinky dye (GenDepot, Barker, 
TX, USA).  
 
2.4. Cellular uptake test of DNA nanoballs 
Cellular uptake of various DNA nanoballs was evaluated by preparing 
fluorescent DNA nanoballs using 25 µM Cy5-dCTP (Perkin Elmer, Boston, MA, 
USA) and DNA nanoballs carrying fluorescent dye-modified ASOs, as described 
above. KB human epidermal carcinoma cells (American Type Culture Collection, 
Rockville, MD, USA) were cultured in RPMI-1640 medium (Welgene, Daegu, 
Korea) supplemented with 10 % fetal bovine serum and 100 units/mL penicillin 
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plus 100 μg/mL streptomycin. KB cells were seeded onto poly-L-lysine coated 
coverslips (BD Biosciences, San Jose, CA, USA) in 24-well plates (SPL Life 
Sciences, Pocheon, Republic of Korea) at a density of 8 × 104 cells/well. The next 
day, cells were treated with Cy5-dCTP–incorporated fluorescent DNA nanoballs or 
fluorescent dye-modified ASO-loaded DNA nanoballs at a concentration of 20 µg 
DNA/well. In some experiments, cells were pre-incubated with 10 µM HA for 2 h 
prior to treatment with DNA nanoballs. For fluorescence microscopy, cells were 
washed and fixed with 4 % paraformaldehyde in phosphate-buffered saline (PBS) 
for 15 min, and stained with 4’,6-diamidino-2-phenylindole dihydrochloride 
(DAPI). The fluorescence of cells was observed using a confocal laser-scanning 
microscope (LSM 5 Exciter; Carl Zeiss, Inc., Jena, Germany). For flow cytometry, 
the cells were harvested and washed three times with cold PBS containing 2 % 
fetal bovine serum, and analyzed using a BD FACSCalibur system equipped with 
Cell Quest Pro software (BD Biosciences).  
 
2.5. Knockdown study of target protein expression 
In vitro silencing of target protein expression by DNA nanoballs was evaluated 
by Western blotting. Various DNA nanoballs were applied to KB cells seeded in 
6-well plates. After 1 h incubation, the cell medium was replaced and cells were 
incubated for an additional 24 h. Whole-cell lysates were then prepared, and 
extracted proteins were quantified using a BCA protein assay kit (Thermo 
Scientific) according to the manufacturer’s instruction. Proteins in samples were 
separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
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(SDS-PAGE) on 10 % gels and then transferred onto polyvinylidene difluoride 
membranes (Hybond-ECL; Amersham Biosciences, Piscataway, NJ, USA). 
Membranes were probed by Western blotting using specific antibodies to c-Jun 
(1:500, sc-1694; Santa Cruz Biotechnology, CA, USA), Hsp27 (1:500, sc-9012; 
Santa Cruz Biotechnology), and glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH; 1:1000, sc25778; Santa Cruz Biotechnology).  
 
2.6. Assessment of DNA nanoball anticancer activity 
The cancer cell-killing effect of various DNA nanoballs was quantitatively 
evaluated using a Cell Counting Kit 8 (CCK-8; Dojindo Laboratories, Kumamoto, 
Japan) and visualized by staining of live cells after treatment with DNA nanoballs. 
KB cells were seeded in 48-well plates at a density of 6 × 104 cells/well. The next 
day, the cells were treated with various types of DNA nanoballs at a constant 
amount of DNA (20 µg/well). After a 1 h incubation in the presence or absence of 
1 µM doxorubicin (Dox), the cell medium was replaced and cells were incubated 
for an additional 24 h. Cell viability was then measured by CCK-8 assay. For 
CCK-8 assays, 20 µL of CCK-8 solution was added to each well and plates were 
incubated for 30 min. The absorbance of the medium at 450 nm was then measured 
colorimetrically using an enzyme-linked immunosorbent assay (ELISA) reader 
(Sunrise-Basic TECAN, Mannedorf, Switzerland). For live cell staining, cells were 
stained with calcein-AM (Molecular Probes, Eugene, OR, USA) after treatment 




2.7. In vivo molecular imaging  
The in vivo tumor distribution of Cy5-dCTP–labeled DNA nanoballs was 
assessed by molecular imaging. Five-week-old athymic nude mice (Orient Bio Inc., 
Seongnam, Korea) were subcutaneously inoculated with 5 × 105 KB cells. After 
tumors had reached a volume of ~100 mm3, fluorescent HMA or MA nanoballs 
were intravenously injected into the mice at a dose of 4 mg DNA/kg. After 1 h, the 
intensity of Cy5 signals was monitored using an eXplore Optix system (Advanced 
Research Technologies Inc., Montreal, Canada) and scanned using a 670 nm laser 
at a power of 25 mW and a count time of 0.3 s/point.   
 
2.8. In vivo study of anti-tumor effects 
The in vivo anti-tumor activity of DNA nanoballs was evaluated by measuring 
tumor growth-inhibitory effects. KB cells (5 × 105 cells) were subcutaneously 
inoculated into the dorsal right side of 5-wk-old athymic nude mice (Orient Bio). 
After tumors had become established, DNA nanoballs and Dox were intravenously 
administrated at a DNA dose of 8 mg/kg and a Dox dose of 3 mg/kg. For MA and 
HMA nanoballs, the doses of ASOs were 2 mg/kg each for Dz13 and OGX-427. 
Mice were treated with the mixture of DNA nanoballs and Dox every other day for 
a total of three injections. Tumor size was measured in two dimensions using a 
slide caliper every 2 days, and tumor volume was calculated as a × b × b × 0.5, 
where a and b are the lengths of the largest and smallest dimensions. The mice 




2.9. Statistics  
All statistical analyses were performed using analysis of variance (ANOVA) 
with a post hoc Student–Newman–Keuls test. SigmaStat software (version 3.5; 
Systat Software, Richmond, CA, USA) was used for the analyses, and a p-value 








3.1. Sequence-specific hybridization of dual ASOs onto DNA nanoballs  
The sequences of scrambled and dual ASO-complementary RCA templates are 
illustrated in Fig. II-1A and II-1B, respectively. ARP was formed by hybridization 
of Dz13 and OGX-427 (Fig. II-1C). Loading amounts of Dz13 and OGX-427 onto 
RCA products depended on the sequences of RCA templates. As compared to RCA 
products of scrambled template, the RCA products of dual ASO-complementary 
RCA templates provided 8.1- and 6.7-fold higher loading amounts for Dz13 and 
OGX-427, respectively (Fig. II-1D). ARP was then treated with adenovirus-derived 
Mu peptide to produce Mu peptide-condensed, dual ASO-loaded DNA nanoballs 
(MA nanoballs). HA was then complexed with MA nanoballs to form HA-coated, 
Mu peptide-condensed, dual ASO-loaded DNA nanoballs (HMA nanoballs) for 
targeted delivery of ASOs to tumors overexpressing the receptor, CD44.  
 
3.2 Characterization of ASO-hybridized DNA nanoballs 
The structures of various DNA nanoballs are illustrated in Fig. II-2A. Mu 
peptide-complexed ARP exhibited nanoball-like structures (Fig. II-2B, II-2C). 
Surface coating of MA nanoballs with HA retained nanoball-like structures (Fig. 
II-2B, II-2C). The size (Fig. II-2D) and zeta potential (Fig. II-2E) of ARP were 
1,242.5 nm ± 320.4 nm and -29.1 mV ± 11.5 mV, respectively. Addition of cationic 
Mu peptide reduced the size to 162.7 nm ± 32.4 nm and increased the zeta 




Fig. II-1. RCA template and hybridization efficiency.  
(A) Secondary structure of scrambled RCA template. (B) Secondary structure of a 
dual ASO-hybridizing RCA template for Dz13 and OGX-427. (C) RCA products 
with poly ASO-binding sequences were hybridized with two ASOs, Dz13 and 
OGX-427, to produce dual ARP. (D) The hybridization efficiencies of the ASOs, 
Dz13 and OGX-427, were tested for products of scrambled RCA templates and 




was 191.4 nm ± 15.1 nm, and the zeta potential was -21.8 mV ± 0.7 mV. Both MA 
nanoballs and HMA nanoballs showed stability against nucleases (Fig. II-2F). 
Upon 30 min treatment with DNase I, ARP was completely degraded and migrated 
to the bottom of agarose gels. In contrast, agarose gel electrophoresis showed no 
degraded DNA fragments of MA nanoballs or HMA nanoballs after DNase I 
treatment. Thus, adenovirus-derived cationic Mu peptide substantially decreased 
the size of ARP, increased their zeta potential values, and provided stability against 
nuclease.  
 
3.3. Cellular uptake of DNA nanoballs and dual ASOs 
HMA nanoballs entered KB cells via CD44 receptors. To visualize and 
quantitate the cellular uptake of DNA nanoballs, we used Cy5-incorporated DNA 
nanoballs by running RCA using Cy5-dCTP. Confocal microscopy (Fig. II-3A) and 
flow cytometry (Fig. II-3B, II-3C) showed little uptake of 
Cy5-dCTP-incoroporated fluorescent ARP or MA nanoballs by 
CD44-overexpressing KB cells, but revealed considerable entry of fluorescent 
HMA nanoballs into KB cells. The enhanced cellular uptake of MA nanoballs 
caused by HA-coating was not observed when the cells were pretreated with free 
HA.  
As a complementary approach, we examined cellular uptake of DNA nanoballs 
containing hybridized, fluorescently labeled ASOs. Consistent with the above 
results, confocal microscopy (Fig. II-4A) and flow cytometry showed considerable 






















Fig. II-2. Schematic illustration and morphology of DNA nanoballs.  
(A) Illustration of the HMA nanoball preparation scheme. Dual ARP were mixed 
with adenovirus core complex-derived Mu peptide to form MA nanoballs. The  
- continued next page - 
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surfaces of MA nanoballs were coated with HA to produce HMA nanoballs. (B,C) 
The morphologies of ARP, MA nanoballs, and HMA nanoballs were observed by 
SEM at different magnifications. Scale bar: 2 um for all groups (B). Scale bar: 800 
nm for ARP and 200 nm for MA nanoball and HMA nanoballs (C). (D) The sizes 
of ARP, MA nanoballs, and HMA nanoballs were measured by dynamic light 
scattering. (E) Zeta potential values of ARP, MA nanoballs, and HMA nanoballs 
were determined by laser Doppler microelectrophoresis. (F) The stability of ARP, 
MA nanoballs, and HMA nanoballs against DNase I was tested by incubation with 
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Fig. II-3. Cellular uptake of DNA nanoballs.  
KB cells were left untreated or were treated with ARP, MA nanoballs or HMA 
nanoballs, with or without HA pre-treatment. Cellular uptake of Cy5-incorporated 
fluorescent DNA nanoballs was visualized by confocal microscopy (A) and 
quantified by flow cytometry (B, C). (B) Representative flow cytometry data. (C) 
Quantification of populations of fluorescence-positive cells. Data are presented as 



















II-4C) into CD44-overexpressing KB cells, but little uptake of these fluorescent 
ASOs when hybridized to MA nanoballs, which lack HA (Fig. II-4D). Again, this  
enhancement of cellular uptake of MA nanoballs by HA-coating was eliminated by 
pretreating cells with free HA. Collectively, these results confirm the CD44 
receptor-dependence of HMA nanoball uptake. 
 
3.4. Reduction of target protein expression by DNA nanoballs  
We next investigated the effect of HMA nanoballs on the expression levels of 
proteins targeted by the dual hybridized ASOs: c-Jun, the target of the DNAzyme 
Dz13, and Hsp27, the target of OGX-427. Downregulation of target proteins was 
monitored by Western blotting (Fig. II-5), which showed that treatment of KB cells 
with HMA nanoballs decreased the protein levels of c-Jun and Hsp27 to 33.0 % ± 
9.5 % (Fig. II-5A) and 12.6 % ± 7.2 % (Fig. II-5B) of control levels, respectively. 
In contrast, treatment of KB cells with HM or MA nanoballs alone did not 
significantly reduce the levels of either protein (Fig. II-5C).  
 
3.5. In vitro anticancer effects of DNA nanoballs  
Among the various DNA nanoballs, HMA nanoballs showed the greatest in 
vitro anticancer effect and synergized with Dox to further enhance anticancer 
efficacy. CCK-8 assay results reveal that the survival of KB cells was not 
significantly reduced by treatment with ARP, HM, or MA nanoballs (Fig. II-6A). 
However, treatment of KB cells with HMA nanoballs reduced the survival of KB 
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Fig. II-4. Cellular uptake of ASOs. 
KB cells were left untreated or were treated with ARP, MA nanoballs or HMA 
nanoballs, with or without HA pre-treatment. (A) Cellular uptake of FAM-Dz13 
and ROX-OGX427 ASOs loaded in DNA nanoballs was visualized by confocal 
microscopy. (B, C) Representative flow cytometry data for cell populations 
positive for FAM-Dz13 (B) and ROX-OGX427 (C) under various conditions. (D) 
Flow cytometry-based quantification of populations of fluorescent (ASO-positive) 



































Fig. II-5. Reduction of target proteins. 
The cellular protein levels of target genes, c-Jun (A) and Hsp27 (B), were 
measured by Western blotting. After various treatments, whole-cell extracts of KB 
cells were analyzed for target proteins by Western blotting. The data are expressed 
as means ± SE (n = 3). (C) Relative intensities of c-Jun and Hsp27 were 
normalized to the GAPDH signal. 
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HMA nanoballs further reduced survival to 51.5 % ± 5.1 % (Fig. II-6A). Similar to 
the CCK-8 assay results, the fluorescent microscopy of live cells exhibited the 
lowest live cell populations in the group treated with HMA nanoballs (Fig. II-6B). 
 
3.6. Biodistribution and in vivo antitumor effects of DNA nanoballs  
We next examined the effect of surface coating with HA on tumor tissue 
accumulation and antitumor effects of intravenously administered MA nanoballs. 
For molecular imaging, Cy5-incorporated fluorescent nanoballs were injected into 
KB cell tumor-bearing nude mice. The tumor tissue distribution of 
Cy5-incorporated HMA nanoballs 1 h post-dose was greater than that of 
Cy5-incorporated MA nanoballs (Fig. II-7A). At 24 h post-injection, total photon 
counts in tumor tissues were 5.9-fold higher in the HMA nanoball-treated group 
than in the MA nanoball-treated group (Fig. II-7B).  
Collectively, these results indicate that surface coating of MA nanoballs with 
HA enhances tumor tissue accumulation. Systemic co-administration of HMA 
nanoballs with Dox synergistically inhibited tumor growth in a KB cell xenograft 
mouse model. Compared to other groups, the HMA nanoball-treated group showed 
























Fig. II-6. In vitro tumor cell-killing effect. 
(A) KB cells were treated with ARP, MA nanoballs, HM nanoballs, or HMA 
nanoballs in the presence or absence of Dox for 1 h. After media replacement, the 
cells were incubated for an additional 24 h. The survival of cancer cells was 
determined by CCK-8 assay. Data are presented as means ± SE (n = 4).  (B) The 
live cell population was stained with calcein-AM and observed by fluorescence 




















Fig. II-7. Biodistribution of ASO-loaded DNA nanoballs.  
(A) KB tumor-bearing mice were intravenously injected with MA nanoballs or 
HMA nanoballs containing Cy5-dCTP. The biodistribution of Cy5 fluorescence 
was visualized using a molecular imaging system. (B) The total photon counts of 
tumor tissues from treated mice were quantified 1 h post-administration by in vivo 



















Fig. II-8. In vivo antitumor effect of ASO-loaded DNA nanoballs.  
KB tumor-bearing mice were intravenously injected with HM nanoballs, MA 
nanoballs, or HMA nanoballs (8 mg DNA/kg) and Dox (3 mg Dox/kg) or with Dox 
alone (3 mg Dox/kg) every other day for a total of three injections. For MA and 
HMA nanoballs, the dose of both ASOs was 2 mg/kg. Tumor sizes were measured 





Here, we demonstrated that the adenovirus-derived Mu peptide played an 
essential role in condensing ARP to form MA nanoballs, and surface coating with 
HA promoted CD44 receptor-mediated delivery of HMA nanoballs to tumor cells. 
Importantly, ASOs delivered by HMA nanoballs silenced the expression of their 
target mRNAs of ASO, exerting potent anticancer effects in vitro and in vivo upon 
co-treatment with Dox.  
The goal of this study was to test the delivery of therapeutic oligonucleotides 
via nucleic acid-based DNA nanoballs using sequence-specific hybridization as a 
loading technique. ssDNA amplified by a RCA reaction can serve as an ASO 
sequence-specific carrier owing to its thousands of complementary sequences to 
the ASO. Compared to a scrambled RCA template, RCA templates containing 
ASO-binding sequences hybridize substantially higher amounts of ASO per RCA 
product (Fig. II-1D). This high hybridization capacity supports the feasibility of 
using hybridization-mediated ASO loading of RCA products for sequence-specific 
ASO delivery.  
Dual ASOs—Dz13 and OGX-427—were loaded onto HMA nanoballs in a 
sequence-specific manner (Fig. II-1B). Dz13 is a DNAzyme with RNA-binding 
hybridization arms that cleaves the mRNA of c-Jun, which is involved in cellular 
proliferation, transformation, and cell death [13]. OGX-427 is known to inhibit the 
expression of Hsp27, which is involved in cancer progression and cell death [14]. 
The adenovirus core complex-derived Mu peptide was used for biomimetic 
condensation of micrometer- to nanometer-sized DNA balls (Fig. II-2). In the 
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absence of Mu peptide, the dual ASO-loaded ssDNAs tended to form a soft, “ball” 
in solution with a diameter of approximately 1.5 µm (Fig. II-2C). Our observations 
are consistent with a previous report, which showed that micrometer-sized DNA 
balls are produced by a RCA reaction [15, 16].The interaction between ARP and 
cationic Mu peptides is electrostatic, resulting in an increase in the zeta potential 
after condensation (Fig. II-2D).  
We observed that uptake of ASO by CD44 receptor-overexpressing KB cells 
was enhanced by delivery using HMA nanoballs compared with MA nanoballs (Fig. 
II-3 and II-4), supporting the role of the HA moiety in enhancing CD44 
receptor-mediated cellular delivery of DNA nanoballs. HA has been previously 
reported to increase the tumor cell delivery of nanoparticles by interacting with 
CD44 receptors; when conjugated to ASOs, it enhances their cellular delivery [17].  
The reduction in target protein levels after treatment of cells with HMA 
nanoballs is attributable to the enhanced uptake of nanoballs via the HA moiety 
and implies effective delivery of ASOs to the interior of the cell. The reduced 
cellular uptake of HMA nanoballs (Fig. II-3) and ASO (Fig. II-4) after pretreatment 
with HA supports the conclusion that the entry of HMA nanoballs into KB cells is 
mediated by the CD44 receptor. Although further study will be required to 
elucidate the intracellular fate of HMA nanoballs, we speculate that HMA 
nanoballs may be partially degraded in endolysosomes, enabling escape of ASOs 
into the cytosol and binding to target mRNA.  
Owing to the greater affinity of the ASOs, Dz13 and OGX-427, for their target 
mRNA compared to that for the complementary ASO-binding sequence, the uptake 
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of HMA nanoballs into cells resulted in the dissociation of ASOs from HMA 
nanoballs and binding to their target mRNA. In addition to the natural preference 
of ASOs for their natural target mRNAs, dissociation of ASOs from ARP was 
further facilitated by modifying the RCA template for complementary binding with 
ASO to contain one mismatched base pair for each ASO. Such facilitated 
dissociation caused by a single mismatch has been previously demonstrated [18].  
We observed the greatest in vivo antitumor effect following combined 
treatment with Dox and HMA nanoballs (Fig. II-8). The target proteins of two 
ASOs, Dz13 and OGX-427, have been reported to be involved in the anticancer 
mechanisms by Dox [26, 27]. Treatment of small lung cancer cells with Dox was 
shown to induce multidrug resistance protein 1 [19]. In the study, the inhibition of 
c-Jun phosphorylation was observed to reduce the Dox-induced multidrug 
resistance protein 1 expression and increase sensitivity of the small lung cancer 
cells to Dox. Overexpression of Hsp 27, the target protein of OGX-427, was found 
to decrease the intracellular level of topoisomerase II, which is important for 
sensitivity and initiation of apoptosis by Dox [20]. Specific inhibitors of c-un and 
Hsp 27 were found to increase chemosensitivity of cancer cells to Dox [21, 22]. 
Inhibition of c-Jun by Dz13 was shown to enhance the sensitivity of cancer cells to 
Dox treatment. A recent study reported that the reduced expression of Hsp 27 by 
resveratrol or short hairpin interfering RNA could sensitize MCF-7 breast cancer 
cells to Dox. Based on these findings, the higher in vivo antitumor activity of 
HMA nanoballs with co-treatment of Dox would be in part due to the enhanced 
chemosensitivity of KB cells to Dox by reduction of c-Jun and Hsp 27. 
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Moreover, the enhanced in vivo antitumor activity in the Dox/HMA nanoball 
co-treatment group could be attributable to the higher tumor accumulation of HMA 
revealed by molecular imaging (Fig. II-7). The improved stability of HMA 
nanoballs against DNase I could contribute to prolonging the circulation of DNA 
nanoballs in serum following intravenous administration. Our in vitro fluorescence 
microscopy and flow cytometry data revealed that the cellular uptake of HMA 
nanoballs and ASO significantly reduced after pre-treatment with free HA, 
supporting the possibility of enhanced tumor distribution of CD44-positive KB 
xenografted mice. Previously, to test whether HA microparticles enter tumor cells 
by CD44 receptor-mediated endocytosis in vivo, the tumor accumulation patterns 
of HA microparticles were compared between CD44-positive and CD44-negative 
tumor bearing mice [23]. Since MA nanoballs and HMA nanoballs differ in the 
surface charges, we can’t exclude the contribution of negative surface charges of 
HMA nanoballs to the in vivo tumor distribution. Future study would be thus 
necessary to compare the distribution and antitumor activity of HMA nanoballs in 
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Chapter III  
 
Polyaptamer DNA nanothread-anchored, reduced graphene 


















DNA aptamers have emerged as a potential targeting moiety for drug-delivery 
systems. DNA aptamers have been chemically conjugated [1] or physically 
complexed [2] to anti-cancer drugs. Carbon nanotubes have been physically 
adsorbed with DNA aptamers for anticancer drug delivery [3]. Notably, surface 
modification of nanoparticles with DNA aptamers has been reported to improve 
tumor accumulation [4,5]. Despite the ability of DNA aptamers to recognize 
specific cellular targets, the wide application of these targeting moieties to drug 
delivery has been hampered in part because their binding affinity is generally 
lower than that of antibodies [6].  
Rolling circle amplification (RCA) is a recently developed molecular technique 
for amplifying single-stranded DNA (ssDNA) from a circular oligonucleotide, 
which acts as a template [7]. The amplified ssDNA contains repeating units of 
sequences complementary to the circular template. RCA has been applied to 
produce multivalent DNA aptamers for detection of small molecules [8] and target 
proteins [9,10]. Moreover, RCA-derived multivalent aptamers have been used to 
capture specific types of cells, showing improved binding affinities compared with 
monovalent DNA aptamers and antibodies in microfluidic devices [11].  
Reduced graphene oxide (rGO) nanosheets have been studied as promising 
materials for anticancer drug delivery [12]. However, rGO nanosheets alone lack 
tumor-targeting ability. Conferring tumor-targeting ability to rGO nanosheets has 
been accomplished through modification with various molecules. Recently, 
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modification with cholesteryl hyaluronic acid has been reported to enhance the 
tumor distribution of rGO nanosheets [13]. However, using aptamers with high 
affinity and specificity represents an important strategy for enhancing the targeted 
delivery of rGO to tumor cells.  
In this study, we hypothesized that coating rGO nanosheets with tumor-specific 
polyaptamer nanothreads would improve the tumor distribution and in vivo 
antitumor efficacy of anticancer drugs. To test this hypothesis, we generated tumor 
cell-specific polyaptamer nanothreads by RCA. Moreover, to enhance the 
anchoring capability of polyaptamers onto rGO, we introduced an oligonucleotide 
bridge sequence between repeating aptamer sequences. As a polyaptamer target, 
we chose protein tyrosine kinase 7 (PTK7), a biomarker for leukemia cells [14,15]. 
Here, we tested whether PTK7 polyaptamer nanothread-anchored rGO nanosheets 
could enhance the delivery of the anticancer drug, doxorubicin (Dox), to 












2. Materials and methods 
 
2.1. Synthesis of polyaptamer nanothreads using RCA 
PTK7 polyaptamer nanothreads without a bridge sequence (PN) or with a 
22-mer T oligonucleotide (oligoT) bridge sequence (PNT) were synthesized using 
RCA reaction. Linear ssDNA templates of PN and PNT were hybridized to an 
RCA primer (Bioneer Corporation, Daejeon, Republic of Korea) designed to bind 
to 3’ and 5’ ends of the template. The sequence of the RCA primer for PN and 
PNT was 5'-CTG CGC CGC CGG GAA AAT ACT G-3'. The sequences of linear 
ssDNA templates were 5'-phosphate-CGG CGG CGC AGC AGT TAG ATT CTA 
ACC GTA CAG TAT TTT CC-3' for PN, and 5'-phosphate-CGG CGG CGC AGC 
AGT TAG ATA AAA AAA AAA AAA AAA AAA AAA TCT AAC CGT ACA 
GTA TTT TCC-3' for PNT. For some experiments, scrambled-sequence 
nanothreads containing an oligoT bridge sequence (SNT) were synthesized using 
an RCA reaction. The sequence of the RCA primer for SNT was 5'-ACT AGT 
CAG ATA TTA CTA TGA C-3', and the sequence of the linear ssDNA template 
for SNT was 5'-phosphate-ATC TGA CTA GTA TAT ACG GCA AAA AAA 
AAA AAA AAA AAA AAA GGT GCG CTC GGT CAT AGT AAT-3'. RCA 
templates for PN, PNT, and SNT are depicted in Fig. 1A. The RCA reaction was 
performed as described previously [16] with slight modifications. Briefly, 0.5 µM 
linear ssDNA template bearing a 5’-phosphate and 3’-hydroxyl group, and an RCA 
primer were first annealed in hybridization buffer (10 mM Tris-HCl pH 8.0, 1 mM 
EDTA, 100 mM NaCl) by heating to 95°C for 5 min and gradually cooling to room 
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temperature over 3 h. The complementary binding of an RCA primer to both ends 
of linear ssDNA allowed the formation of a circular ssDNA with a nick between 3’ 
and 5’ ends. The nick in the circular DNA was closed by adding 125 units/ml T4 
DNA ligase (Thermo Scientific, Waltham, MA, USA) to 1 ml of reaction mixture 
and incubating at 4°C for 12 h. π29 DNA polymerase (100 units/ml; Thermo 
Scientific), RCA reaction buffer, and 2 mM dNTP (Intron Biotechnology, Seoul, 
Republic of Korea) were then added to the ligation mixture and incubated at 30°C 
for 5 min. Thereafter, π29 DNA polymerase was inactivated by heating at 70°C for 
10 min, and the remaining dNTP was removed by size-exclusion chromatography 
using a PD-10 desalting column (GE Healthcare, Buckinghamshire, UK). The 
resulting RCA products were stored at 4°C until use. 
 
2.2. Preparation of rGO nanosheets 
Graphene oxide (GO) nanosheets were prepared from graphite by Hummer’s 
method. In brief, 0.5 g graphite powder (Sigma-Aldrich, St. Louis, MO, USA), 3 g 
KMnO4 (Sigma-Aldrich), and 0.5 g NaNO3 (Sigma-Aldrich) were added to 23 ml 
cold H2SO4. After stirring for 1 h at 35°C, 46 ml water was added and the mixture 
was incubated at 90°C for 1 h. The reaction was stopped by adding 140 ml of 
water and 10 ml of 30 % H2O2. The product was purified by washing four times 
with centrifugation at 1600 × g, first with 5 % HCl and then three times with 
triple-distilled water (TDW). The product was dispersed in TDW and sonicated for 
2 h to exfoliate GO layers to GO nanosheets. Unexfoliated GO layers were 
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removed by centrifugation at 1600 × g for 10 min. The supernatant was filtered 
through 0.2-µm polycarbonate membrane filters (Millipore Corp., Billerica, MA, 
USA) using an extruder (Northern Lipid, British Columbia, Canada).  
rGO nanosheets were synthesized by reduction of GO nanosheets as previously 
described [13]. Briefly, 2 ml of GO nanosheets in water was mixed with 8 ml of 
water, 0.5 ml of ammonia solution (28 wt% in water; Junsei Chemical, Tokyo, 
Japan), and 5 µl of hydrazine monohydrate (64 % in water; Sigma-Aldrich). The 
mixture was stirred in a water bath at 80°C for 10 min. After cooling to room 
temperature, the remaining hydrazine and ammonia were eliminated by dialysis 
(MWCO 100K; Spectrum Laboratories, Inc., Rancho Dominguez, CA, USA) 
against TDW.  
 
2.3. Anchoring nanothreads onto rGO nanosheets 
PN-anchored rGO nanosheets (PNrGO), PNT-anchored rGO nanosheets 
(PNTrGO), and SNT-anchored rGO nanosheets (SNTrGO) were prepared by 
mixing nanothreads with the corresponding rGO nanosheets at a weight ratio of 
0.5:1 (nanothread:nanosheet) and incubating at room temperature for 10 min. 
Anchoring efficiency of nanothreads was evaluated using a gel-retardation assay. 
Briefly, nanothreads and rGO nanosheet reaction mixtures were loaded onto a 
0.8 % agarose gel containing 0.5 µg/mL ethidium bromide and electrophoresed for 
30 min at 50 mV in Tris-borate-ethylenediamine-tetraacetic acid buffer. For 
comparison, free PN or PNT was loaded onto the gel. The migration of 
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rGO-unbound nanothreads was visualized using a Gel Doc System (Bio-Rad Lab., 
Hercules, CA, USA).  
 
2.4. Characterization of nanothread-anchored rGO nanosheets 
Nanothread-anchored rGO nanosheets were characterized by assessing 
morphology, size, zeta potential, and stability in aqueous solution. The 
morphology of PNT and PNTrGO was examined by transmission electron 
microscopy (TEM) using a JEM1010 transmission electron microscope (JEOL, 
Tokyo, Japan). The sizes of rGO nanosheets with or without nanothreads were 
measured using dynamic light scattering. The zeta potential values of rGO 
nanosheets with or without nanothreads were measured by laser Doppler 
microelectrophoresis at an angle of 22° using an ELS-8000 instrument (Photal, 
Osaka, Japan). The stability of rGO and PNTrGO was investigated by allowing a 
suspension of rGO or PNTrGO in phosphate-buffered saline (PBS; 50 mM, pH 
7.4) to stand at room temperature, with periodic monitoring samples for the 
appearance of precipitates. 
 
2.5. Loading of Dox onto rGO nanosheets 
Dox was loaded onto rGO, SNTrGO, and PNTrGO by physical adsorption. 
Dox-loaded rGO (Dox/rGO), Dox-loaded SNTrGO (Dox/SNTrGO), and 
Dox-loaded PNTrGO (Dox/PNTrGO) were generated by adding Dox to the 
corresponding rGO nanosheets at a weight ratio of 1:5 (Dox:rGO nanosheets) and 
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incubating at room temperature for 10 min. Free Dox was then removed using a 
PD-10 desalting column (GE Healthcare). The extent of Dox loading onto various 
rGO nanosheets was determined by measuring the loss of Dox fluorescence at 485 
nm caused by the quenching of rGO-adsorbed Dox using a fluorescence microplate 
reader (Gemini XS; Molecular Devices, Sunnyvale, CA, USA). 
 
2.6. Preparation of fluorescent-marker–labeled rGO nanosheets 
For cellular uptake studies and molecular imaging, PNTrGO and SNTrGO 
were labeled with cyanine 5.5 dye (Cy5.5) conjugated to the lipid, 
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene 
glycol)-5000] (DSPE-PEG5000-NH2), containing PEG with a molecular weight of 
5,000 (NOF Corporation, Tokyo, Japan). First, 4.5 mg of 1,2-DSPE-PEG5000-NH2 
was dissolved in 2 ml of 0.1 M sodium bicarbonate buffer (pH 8.3), after which 1.0 
mg of Cy5.5 NHS ester (Lumiprobe, Hallandale Beach, FL, USA) in 100 µl 
dimethyl sulfoxide was added with stirring for 4 h in the dark. The resulting 
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[poly(ethylene 
glycol)5000-N`]-cyanine 5.5 (DSPE-PEG5000-Cy5.5) was purified using a 
self-packed Sephadex G15 column (GE Healthcare) and stored at 4°C until use. 
For labeling of various rGO nanosheets with DSPE-PEG5000-Cy5.5, 100 µl of the 
corresponding rGO nanosheet solution (1 mg/ml) was mixed with 10 µl 
DSPE-PEG5000-Cy5.5 (10 mg/ml). After sonication for 30 min, unbound 
DSPE-PEG5000-Cy5.5 was removed by dialyzing the mixture (MWCO 1000K; 
Spectrum Laboratories, Inc.) against TDW for 24 h.  
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2.7. Cell culture  
Human T-cell acute lymphoblastic leukemia (CCRF-CEM) cells and human 
Burkitt’s lymphoma (Ramos) cells (Korean Cell Line Bank, Seoul, Republic of 
Korea) were cultured in RPMI-1640 medium (Welgene, Daegu, Republic of 
Korea) supplemented with 10 % fetal bovine serum and 100 units/ml penicillin 
plus 100 μg/ml streptomycin. The cells were grown at 37°C in a humidified 5 % 
CO2 atmosphere.   
 
2.8. PTK7 expression study  
The expression of PTK7 on the surfaces of CCRF-CEM and Ramos cells was 
evaluated using flow cytometry. After harvesting, cells were incubated for 30 min 
at 4°C in cold PBS containing 3 % bovine serum albumin. Next, cells were washed 
and incubated for 30 min at 4°C with a monoclonal R-phycoerythrin 
(PE)-conjugated anti-PTK7 antibody (Miltenyi Biotec, Bergisch Gladbach, 
Germany) diluted 1:10 in cold PBS containing 2 % fetal bovine serum. Cells 
expressing PTK7 on the surface were identified by detection of fluorescent 
monoclonal antibodies. 
 
2.9. Cellular uptake study 
Cellular uptake of various rGO nanosheets was evaluated using confocal 
microscopy and flow cytometry. CCRF-CEM or Ramos cells were seeded onto 
48-well plates at a density of 8 × 104 cells/well. After overnight incubation, cells 
were treated with DSPE-PEG5000-Cy5.5–labeled rGO, SNTrGO or PNTrGO for 15 
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min, washed three times with PBS containing 2 % fetal bovine serum, and 
evaluated by confocal microscopy or flow cytometry. For flow cytometry, the cells 
were analyzed using a BD FACSCalibur system equipped with Cell Quest Pro 
software (BD Biosciences, San Jose, CA, USA). For confocal microscopy, the 
cells were transferred onto poly-L-lysine coated plates (BD Biosciences) and 
incubated for 1 h to allow cells to attach. Cells were then fixed with 4% 
paraformaldehyde in PBS for 15 min and stained with 
4’,6-diamidino-2-phenylindole dihydrochloride (DAPI). Cy5.5 fluorescence was 
observed using a confocal laser-scanning microscope (LSM 5 Exciter; Carl Zeiss, 
Inc., Jena, Germany).  
 
2.10. In vitro anticancer activity assay 
In vitro anticancer effects of Dox/rGO, Dox/SNTrGO, and Dox/PNTrGO were 
assessed against CCRF-CEM and Ramos cells. CCRF-CEM and Ramos cells were 
seeded into 48-well plates at a density of 4 × 104 cells/well. After overnight 
incubation, the cells were treated for 1 h with Dox/rGO, Dox/SNTrGO, or 
Dox/PNTrGO (2 µM Dox). The culture medium was then replaced, cells were 
incubated for an additional 24 h, and viability was measured using a Cell Counting 
Kit 8 (CCK-8; Dojindo Laboratories, Kumamoto, Japan) or live-cell staining assay 
(Molecular Probes, Eugene, OR, USA). For CCK-8 assays, 20 µl of CCK-8 
solution was added to each well. After incubating for 30 min, the absorbance of the 
medium was measured colorimetrically at 450 nm using an enzyme-linked 
immunosorbent assay reader (Sunrise-Basic; TECAN, Mannedorf, Switzerland). 
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For live-cell staining assays, live cells were stained with calcein-AM after a 1 h 
treatment with Dox/rGO, Dox/SNTrGO, or Dox/PNTrGO.  
 
2.11. In vivo molecular imaging  
The biodistribution of DSPE-PEG5000-Cy5.5-labeled SNTrGO and PNTrGO in 
mice was observed by molecular imaging. CCRF-CEM cells (5 × 106) in a PBS 
solution containing 50 % matrigel (BD Biosciences) were subcutaneously 
inoculated into the dorsal right flank of 5-wk-old athymic nude mice (Orient Bio, 
Inc., Seongnam, Republic of Korea). After tumors had become established, 
DSPE-PEG5000-Cy5.5-labeled, nanothread-anchored rGO nanosheets were 
intravenously administered into mice at a dose of 1 mg/kg. At various time points 
after intravenous injection, Cy5.5 signals of mice were scanned using an eXplore 
Opitx system (Advance Research Technologies Inc., Montreal, Canada) with a 
laser power of 25 mW and a count time of 0.3 s/point. A 670-nm pulsed-laser 
diode was used to excite Cy5.5. Long-wave fluorescence emission was detected 
with a fast photomultiplier tube (Hamamatsu Photonics, Hamamatsu, Japan) and a 
time-correlated single-photon counting system (Becker and Hickl GmbH, Berlin, 
Germany). 
 
2.12. In vivo anti-tumor activity assay 
The anti-tumor effects of Dox administered on various rGO nanosheets were 
tested using CCRF-CEM tumor-bearing mice. Five week-old athymic nude mice 
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were subcutaneously injected in the dorsal right flank with 5 × 106 CCRF-CEM 
cells in 50 % matrigel/PBS. When the tumors had grown to 150–180 mm3, the 
mice were intravenously administered 3 mg/kg of Dox (15 mg/kg) as Dox/rGO, 
Dox/SNTrGO, or Dox/PNTrGO every other day for a total of three injections. 
Tumor size was measured in two dimensions using a slide caliper every other day, 
and tumor volume was calculated as a × b × b × 0.5, where a is the largest and b is 
the smallest dimension. For histopathological analyses, tumor tissues were excised 
and weighed on day 12. The sections were stained with anti-proliferating cell 
nuclear antigen (PCNA) antibody [17], and assayed using terminal 
deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) [17]. 
 
2.13. Statistics  
All data were statistically analyzed using ANOVA with post hoc Student–
Newman–Keuls test. SigmaStat software (version 3.5; Systat Software, Richmond, 
CA, USA) was used for analyses, and a p-value less than 0.05 was considered 












3.1. Effects of the oligoT bridge on nanothread anchoring to rGO 
The effects of the oligoT bridge sequences on nanothread anchoring were 
tested by first producing PN, and PNT by the RCA reaction, as depicted in Fig. 
III-1A. Unlike the case for PN, a 22-mer A oligonucleotide sequence was included 
within the linear ssDNA template of PNT to produce oligoT in the RCA product. 
PN or PNT was mixed with rGO at a weight ratio of 0.5:1 to produce PNrGO or 
PNTrGO (Fig. III-1B). Gel retardation assays showed the presence of migrating 
unbound DNA nanothreads in PNrGO complexes but not in PNTrGO complexes 
(Fig. III-1C). These results indicate that the oligoT bridge sequences improved the 
ability of RCA nanothreads to anchor onto rGO nanosheets.  
 
3.2. Physicochemical properties of PNTrGO 
The morphology, size, zeta potential, and stability of PNTrGO in buffer were 
characterized. Transmission electron microscopy (TEM) showed that PNT alone 
exhibited a nanothread-like morphology (Fig. III-2A). TEM of PNTrGO revealed 
the presence of PNT anchored on rGO nanosheets (Fig. III-2B). Anchoring of PNT 
onto rGO nanosheets did not significantly affect the mean size of rGO nanosheets 
(Fig. III-2C), but did decrease zeta potential values (Fig. III-2D). Moreover, PNT 
coating enhanced the dispersion stability of rGO nanosheets in PBS (Fig. III-2E). 
Plain rGO nanosheets formed precipitates in PBS within 1 day. In contrast, 






















Fig. III-1. Schematic illustration of PNrGO and PNTrGO nanosheets. 
(A) Templates of PN, PNT, and SNT for RCA. (B) Schematic representation of 
PNrGO and PNTrGO. (C) Complexation of rGO nanosheets with PN or PNT was 
analyzed by electrophoresis on 0.8 % (w/v) agarose gels. 
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Moreover, the loading efficiencies of Dox onto rGO (99.9 % ± 0.1 %) and 
PNTrGO (99.9 % ± 0.2 %) were not significantly different.  
 
3.3. Enhanced cellular uptake of PNTrGO nanosheets in PTK7-positive 
cells 
The cellular uptake of PNTrGO was enhanced in PTK7-positive cells, but not 
in the PTK7-negative cells. The dependence of PNTrGO uptake on PTK7 
expression was tested by flow cytometry and fluorescence microscopy. Flow 
cytometry showed that PTK7 was not expressed on the surface of Ramos cells (Fig. 
III-3A), but was highly expressed on CCRF-CEM cells (Fig. III-3B), consistent 
with a previous report [18]. In PTK7-negative Ramos cells, the uptake of 
DSPE-PEG5000-Cy5.5-labeled PNTrGO was not significantly different from that of 
DSPE-PEG5000-Cy5.5-labeled SNTrGO, as determined by fluorescence microscopy 
(Fig. III-3C). In contrast, PTK7-positive CCRF-CEM cells showed greater uptake 
of fluorescent dye-labeled PNTrGO than fluorescent dye-labeled SNTrGO (Fig. 
III-3D). Consistent with these fluorescence microscopy data (Fig. III-3C, III-3D), 
flow cytometry revealed that notable cellular uptake of PNTrGO occurred in 
CCRF-CEM cells (Fig. III-3F), but not in Ramos cells (Fig. III-3E).  
 
3.4. In vitro anticancer effects of Dox/PNTrGO nanosheets 
Consistent with cellular uptake patterns, Dox/PNTrGO exhibited enhanced 
anticancer activity in PTK7-positive CCRF-CEM cells, but not in PTK7-negative 



















Fig. III-2. Characterization of nanothread-anchored rGO nanosheets. 
The morphology of PNT (A) (scale bar, 200 nm) and PNTrGO nanosheets (B) 
(scale bar, 100 nm) was observed by TEM. (C) The sizes of rGO and PNTrGO 
were measured by dynamic light scattering. (D) Zeta potential values of rGO and 
PNTrGO were determined by laser Doppler microelectrophoresis at an angle of 
22° using an ELS-8000 instrument. (E) The stability of rGO and PNTrGO was 





















Fig. III-3. Cellular uptake of various rGO nanosheets in PTK7-positive 
and -negative cells. 
Ramos cells (A) and CCRF-CEM cells (B) were stained with fluorescent 
anti-PTK7 antibody, and fluorescence-positive cells were measured by flow 
- continued next page - 
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cytometry. (C, E) Ramos cells were left untreated or were treated with rGO, 
SNTrGO, or PNTrGO. (D,F) CCRF-CEM cells were left untreated or were treated 
with rGO, SNTrGO, or PNTrGO. For detection of cellular uptake, rGO nanosheets 
were labeled with DSPE-PEG5000-Cy5.5. After incubation for 15 min, cellular 




















differ with respect to modification of rGO with PNT or SNT. In contrast, the 
anticancer activity of Dox toward CCRF-CEM cells was significantly higher 
following delivery with PNTrGO compared to delivery with rGO or SNTrGO (Fig. 
III-4B). Treatment of CCRF-CEM cells with Dox on PNTrGO reduced the 
viability of the cells to 43.1 % ± 9.2 % of that in control cells. Fluorescent 
dye-based live-cell staining assays revealed that the killing effect of Dox was 
greater when delivered by PNTrGO in CCRF-CEM cells (Fig. III-4D), but not in 
Ramos cells (Fig. III-4C). 
 
3.5. Tumor tissue accumulation of nanothread-anchored rGO 
nanosheets 
Following intravenous administration into CCRF-CEM tumor-bearing mice, 
fluorescent dye-labeled PNTrGO exhibited preferential tumor tissue accumulation. 
Compared with mice in fluorescent rGO and SNTrGO treatment groups, 
PNTrGO-treated mice showed tumor localization of fluorescence signal at 1 h (Fig. 
III-5A), 24 h (Fig. III-5B), and 48 h (Fig. III-5C). At 48 h, fluorescence intensity 
(photon count values) in tumor tissues was 2.3- and 2.5-fold higher in the 
PNTrGO-treated group than in groups treated with SNTrGO or rGO, respectively 


























Fig. III-4. In vitro anticancer effects of Dox delivered using 
nanothread-anchored rGO nanosheets . 
(A) A schematic depiction of Dox/PNTrGO is shown. (B) CCRF-CEM or Ramos 
- continued next page - 
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cells were treated with rGO, Dox/SNTrGO, or Dox/PNTrGO for 1 h. Untreated 
cells were used as a control. After incubation for an additional 24 h, the viability of 
cells was measured by CCK-8 assay. The results are the means ± SE of three 
independent experiments (*p < 0.05 compared to other groups; ANOVA and 
Student-Newman-Keuls test). Live Ramos cells (C) and CCRF-CEM cells (D) 



































Fig. III-5. Biodistribution of nanothread-anchored rGO nanosheets. 
CCRF-CEM tumor-bearing mice were intravenously injected with rGO, SNTrGO, 
or PNTrGO. DSPE-PEG5000-Cy5.5 was used to label various rGO nanosheets for 
imaging. After 1 h (A), 24 h (B) and 48 h (C), the in vivo distribution of rGO 
nanosheets was visualized using a molecular imaging system. (D) Total photon 
counts in tumor sites relative to that in the untreated group were quantified 48 h 
post-dose using an in vivo imaging system (*p < 0.05 compared to other groups; 
ANOVA and Student-Newman-Keuls test). 
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3.6. In vivo anticancer effects of Dox delivered by various 
nanothread-anchored rGO nanosheets  
Delivery of Dox by intravenous administration of Dox/PNTrGO produced the 
greatest antitumor effects against CCRF-CEM tumors in mice. On day 12, tumor 
volumes in mice treated with Dox/PNTrGO were significantly lower than those in 
mice treated with Dox/SNTrGO or Dox/rGO. In Dox/PNTrGO-treated mice, tumor 
volume was reduced to 23 % of that in untreated mice (Fig. III-6A), and tumor 
weight was reduced to 12 % (Fig. III-6B). In keeping with these tumor-growth–
inhibitory effects (Fig. III-6A), PCNA staining showed that the proliferating cell 
population was lowest in tumor tissues of mice treated with Dox/PNTrGO (Fig. 
III-7A, III-7C). Moreover, TUNEL assays revealed that the apoptotic cell 
population in tumor tissues of mice treated with Dox/PNTrGO was 2.1- and 
2.5-fold larger than that in Dox/SNTrGO-treated and Dox/rGO-treated groups, 




























Fig. III-6. In vivo antitumor effects of Dox on nanothread-anchored 
rGO nanosheets.  
(A) CCRF-CEM tumor-bearing mice were treated three times by intravenous 
administration of 3 mg/kg of Dox on rGO, SNTrGO, or PNTrGO every other day 
(B) On day 12, tumor tissues were excised and weighed (n = 4; *p < 0.05 
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Fig. III-7. Immunohistochemistry of tumor tissues. 
Tumor tissues excised on day 12 after tumor inoculation were analyzed by 
immunostaining for PCNA (A) and by performing TUNEL assays (B). The 
numbers of PCNA-immunostained proliferating cells (C) and TUNEL-labeled 
apoptotic cells (D) in tumor tissue sections were determined (n = 4; *p < 0.05 






















Here, we demonstrated that PNTrGO nanosheets can be used for targeted 
delivery of anti-cancer drugs to PTK7-positive tumor tissues. The introduction of 
an oligoT bridge between aptamer sequences increased the ability of RCA 
nanothreads to anchor onto rGO nanosheets. Surface modification of rGO with 
PNT resulted in improved cellular uptake into PTK7-positive tumor cells lines and 
enhanced tumor tissue accumulation compared to SNTrGO nanosheets. Moreover, 
systemic administration of Dox using PNTrGO enhanced the antitumor effects in 
mice bearing PTK7-positive tumors.  
TEM analyses revealed that PTK7-targeting polyaptamer sequences produced 
by RCA of ssDNA templates exhibited a nanothread-like morphology (Fig. III- 
2A). In RCA reactions, π29 DNA polymerase replicates circular DNA templates 
over many rounds to yield products typically tens of thousands of nucleotides long 
[10,19].  
We observed that PNT showed a greater ability to bind rGO nanosheets than 
PN (Fig. III-1C). The single-stranded oligoT bridge between each PTK7 aptamer 
sequence may serve as an rGO-anchoring unit. It has been reported that 
graphene-based nanosheets are capable of adsorbing ssDNA via π-π stacking 
interactions between the ring structures in the nucleobases. Graphene-based 
nanosheets are known to have lower affinity for dsDNA or ssDNA with secondary 
and tertiary structure owing to shielding of nucleobases within the negatively 
charged phosphate backbone [20]. Since PTK7 aptamers possess a specific tertiary 
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structure that enables binding to PTK7, the affinity of PTK7 aptamer alone for 
rGO nanosheets might be expected to be lower than that of oligoT sequences. 
Consistent with this supposition, the addition of oligoT sequence increased the 
binding of nanothreads onto rGO nanosheets.  
In addition to conferring PTK7-recognition ability, PNT on rGO could serve as 
a dispersion stabilizer of rGO nanosheets in PBS. Poor solubility and aggregation 
in physiological buffers in the presence of salts have been linked to safety concerns 
surrounding the use of graphene-based nanosheets. Chemical modifications of 
surfaces with hydrophilic polymers such as PEG have been used to enhance the 
stability of graphene-based nanosheets [21]. In this latter study, adsorption of DNA 
onto the surface of GO nanosheets was reported to increase stability in aqueous 
solutions for several months, completely preventing aggregation [22]. The 
enhanced stability of PNTrGO in PBS observed here might offer greater stability 
of rGO nanosheets in serum after systemic administration.  
PNTrGO was taken up by CCRF-CEM cells with greater efficiency than 
SNTrGO (Fig. III-3F). This enhanced cellular uptake of PNTrGO is attributable to 
the expression of PTK7 on CCRF-CEM cells (Fig. III-3B), as evidenced by the 
diminished uptake of PNTrGO by PTK7-negative Ramos cells (Fig. III-3A). 
Moreover, upon binding ligands, namely the PTK7-targeting DNA aptamer sgc8, 
PTK7 has been shown to undergo endocytosis [18], a crucial mechanism in the 
cellular entry of nanocarriers.  
To visualize the cellular uptake and in vivo fate of PNTrGO, we labeled the 
surfaces of PNTrGO with the fluorescent lipid dye, DSPE-PEG5000-Cy5.5, which 
87 
 
adheres to the surfaces of rGO through hydrophobic interaction. Although 
graphene-based nanosheets exert a strong quenching effect on fluorescent probes, 
providing a sufficient distance from the surfaces of nanosheets can prevent 
fluorescence resonance energy transfer, thereby avoiding quenching. The relatively 
long PEG spacer in the DSPE-PEG5000-Cy5.5 fluorescent lipid used here thus 
minimizes quenching upon adsorption to rGO surfaces.  
Our in vivo molecular imaging data revealed that PNTrGO nanosheets 
exhibited enhanced tumor distribution (Fig. III-5D). The greater tumor distribution 
of PNTrGO implies that PNT was not degraded in the systemic circulation, and 
was capable of recognizing and binding PTK7-expressing tumor cells upon arrival 
in tumor tissues. The adsorption of PNT onto rGO may have contributed to the 
enhanced stability of PNT against the nuclease-rich in vivo environment. Indeed, 
graphene-based nanosheets have been previously reported to protect DNA 
adsorbed onto the graphene surface from nuclease digestion [23]. Specifically, this 
latter study showed that a molecular beacon adsorbed onto graphene oxide surfaces 
was protected from enzymatic cleavage and was delivered to targeted cells, 
resulting in visualization and detection of intracellular survivin mRNA [24]. 
Another study reported enhanced nuclease resistance of ATP aptamers upon 
adsorption to graphene oxide nanosheets. 
The anti-cancer effects of Dox were greatest both in vitro and in vivo after 
delivery using PNTrGO (Figs. III-4 and III-6). Although the release profile of Dox 
from graphene-based nanosheets is not fully characterized, it has been reported that 
release of Dox loaded onto pegylated GO nanosheets is facilitated in an acidic 
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solution (pH 5.5), and is reduced at more neutral pH values (pH 7.4) [25]. 
Accordingly, as suggested by the results of a previous study , after endocytosis via 
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Chapter IV  
 
















DNA has recently emerged as a biomaterial for drug-delivery systems. One 
specific class of drug-delivery systems is three-dimensional hydrogels. Although 
these hydrogels have attracted interest for possible biological and medical 
applications, the development of DNA-based hydrogels with designable properties 
is still in its early stages. DNA hydrogels are natural, biocompatible and 
biodegradable [1]. DNA hydrogels have been studied as drug-delivery [2] and 
gene-delivery [3] vehicles, and as biosensors [4,5].  
DNA hydrogels have been prepared by hybridization of nucleic acid units with 
chemical or DNA cross-linkers. Ethylene glycol diglycidyl ether [6,7] and 
azobenzene [8] have been used as DNA hydrogel chemical cross-linkers. DNA 
molecules with sticky ends also serve as cross-linkers to form three-dimensional 
DNA hydrogels [9,10].  
Until now, little attention has been paid to the functionality and drug specificity 
of DNA molecules used for DNA hydrogel matrices. Recently, CpG 
sequence-containing DNA hydrogels were studied for their ability to confer 
immunomodulation [2]. A previous study reported DNA hydrogels designed to 
deliver doxorubicin [11]. In the study, drug loading onto DNA hydrogels was 
produced by non-specific electrostatic interactions between the positively charged 
drug molecule and negatively charged DNA, which may limit the application of 
hydrogels to positively charged drugs. 
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In this study, we propose an injectable DNA hybrid hydrogel using 
single-stranded DNA (ssDNA) and polyaptamer sequences as a drug-specific 
hydrogel matrix and graphene oxide (GO) nanosheets as a cross-linker. GO 
interacts with ssDNA, but not with double-stranded DNA [12,13], a property we 
exploited in selecting GO as a cross-linker in ssDNA-sequence–containing 
hydrogels. Drug-specificity was provided to DNA hydrogel matrices by 
introducing a drug-specific polyaptamer sequence between GO-binding ssDNA. 
Drug-specific polyaptamer and GO-binding ssDNA sequences were obtained by 
rolling-circle amplification (RCA), and then cross-linked in the presence of GO. 
Here, we report the construction, rheology, and drug specificity of GO-crosslinked 















2. Materials and methods 
 
2.1. Synthesis of rGO nanosheets 
GO nanosheets were prepared from graphite powder according to a 
modification of Hummer’s method, as described previously [14]. In brief, graphite 
powder (0.5 g; Sigma-Aldrich, St. Louis, MO, USA) was added to cold H2SO4 (23 
ml) and stirred on ice, after which KMnO4 (3 g) and NaNO3 (0.5 g) were added 
slowly. Following continuous stirring for 1 h at 35°C, 46 ml of triple-distilled 
water (TDW) was added and the solution was incubated for 1 h at 90°C. The 
reaction was stopped by adding 140 ml TDW and 10 ml 30 % H2O2. The product 
was thoroughly washed and purified by repeated centrifugation of the resulting 
mixture. The purified product was suspended in TDW and sonicated for 2 h to 
exfoliate the agglomerated GO layers into single GO nanosheets. Unexfoliated GO 
was removed by centrifugation, and the supernatant containing GO nanosheets was 
collected. 
 
2.2. Preparation of circular ssDNA template for RCA 
Circular DNA templates for RCA were prepared using a 5’-phosphorylated 
linear ssDNA template. The phosphorylated linear ssDNA template was composed 
of an RCA primer-complementary sequence for circle formation, a GO binding 
12-mer oligo A sequence, and a kanamycin-binding aptamer to provide drug 
specificity. The sequence of the primer was 5’-GTA CGT GCT AGC CGA TAT 
GCC T-3’, and the sequence of the polyaptamer template was 5’-phosphate-ATC 
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GGC TAG CAC GTA CAG AAC TAA AAA AAA AAA AGT CGG CTT AGC 
CTC AAC CCC CAA GGC AAA AAG GCA T-3’, where the underlined 21-mer is 
an aptamer sequence for kanamycin [15]. In some experiments, a control RCA 
template in which the kanamycin-specific aptamer sequence was replaced with a 
scrambled random sequence with the same number of bases (5’-phosphate-ATC 
GGC TAG CAC GTA CAG AAC TAA AAA AAA AAA AGT GCG CTC GGT 
CAT AGT ACG GAA GGC AAA AAG GCA T-3’) was used. In experiments 
designed to test the role of 12-mer oligo A, a polyaptamer template lacking the 
12-mer oligo A (5’-phosphate-ATC GGC TAG CAC GTA CAG AAC TGT CGG 
CTT AGC CTC AAC CCC CAA GGC AAA AAG GCA T-3’) was used. The linear 
ssDNA template and circular-form–inducing RCA primers were from Bioneer Co. 
(Daejeon, Republic of Korea). For RCA, 5’-phosphorylated linear ssDNA template 
(0.5 µM) was mixed with 0.5 µM of its corresponding primer in 1 ml of 
hybridization buffer (10 mM Tris-HCl, 1 mM EDTA, 100 mM NaCl, pH 8.0). The 
solution was thoroughly vortexed, heated for 5 min at 95°C, and then allowed to 
cool slowly to 30°C over a 3 h period. The primer-hybridized circular template (50 
nM) was reacted with 25 µl (equivalent to 125 Weiss units) of T4 DNA ligase 
(Thermo Fisher Scientific Inc., Waltham, MA, USA) in 1 ml of T4 DNA ligase 
reaction buffer for 12 h at 4°C. The solution was then incubated for 10 min at 70°C 
to inactivate the ligase and stored at -20°C until use.  
 
2.3. RCA-mediated synthesis of GO-PA hybrid hydrogels 
Kanamycin-specific polyaptamer-based hydrogels with GO as a crosslinker 
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were synthesized by amplifying circular RCA templates in the presence of GO 
nanosheets. Circular ssDNA template (10 nM) containing a 21-bp 
kanamycin-specific aptamer sequence or scrambled DNA sequence was treated 
with a 10 mM dNTP mix (Applied Biosystems, Seoul, Republic of Korea) and π29 
DNA polymerase (volume equivalent to 1 % of the total reaction volume) in 1.2 ml 
of π29 DNA polymerase reaction buffer (Thermo Fisher Scientific Inc.). The 
mixture was vortexed, and the RCA reaction was allowed to proceed at 30°C for 
0.5 h. GO (200 µg) was then added and, after vortexing the mixture for 30 s, the 
RCA reaction was continued for 11.5 h. The resulting GO-PA hybrid hydrogels or 
GO-crosslinked scrambled (GO-SC) hydrogels were kept at room temperature until 
use.  
 
2.4. Scanning electron microscopy  
The morphology of GO-PA hybrid hydrogels was observed by scanning 
electron microscopy (SEM). GO-SC or GO-PA hydrogels were spray-coated with 
Au/Pd. The coated samples were then placed onto a 12-mm diameter copper grid 
(FESEM Finder grid; Ted Pella Inc., Redding, CA, USA), and SEM images were 
obtained using a Field-Emission SEM/FIB (focused ion beam) system (Carl Zeiss 
Inc., Thornwood, NY, USA). 
 
2.5. Measurement of GO-PA hybrid hydrogel swelling ratios 
The swelling ratio of hydrogels was calculated from their water uptake capacity. 
GO-PA hybrid hydrogel was dehydrated by freeze-drying (FreeZone 2.5; Labconco, 
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MO, USA). The dehydrated hydrogel was then immersed in 2 ml of TDW and 
incubated at 37°C. At predetermined time points, the hydrogel was removed, 
blotted with tissue paper, and weighed. The swelling ratio of the hydrogel was 
calculated from the following equation: Swelling ratio (%) = [(Ws – Wi)/Wi] × 100, 
where Wi represents the weight of the dehydrated hydrogel and Ws the weight of 
the rehydrated hydrogel.  
 
2.6. Rheology and X-ray diffraction pattern measurements  
A rotational rheometer (DHR-1; TA Instruments Ltd., DE, USA) was used to 
measure rheological properties of the GO-PA hybrid hydrogel. The hydrogel was 
placed on the plate of the rheometer, and shear storage and loss modulus were 
measured using dynamic frequency sweeping mode with strain fixed at 5 %. The 
X-ray diffraction (XRD) patterns of dried plain GO and GO-PA hybrid hydrogels 
were analyzed using a high resolution X-ray diffractometer (D8 Discover; Bruker 
Corp., Billerica, MA, USA). 
 
2.7. Loading of kanamycin into GO-PA hybrid hydrogels  
Kanamycin was loaded into GO-PA hydrogels through aptamer-target specific 
interactions. Hydrogels (1.8 mg) were immersed in 1 ml of kanamycin sulfate (100 
µg/ml) in TDW for 10 min. Hydrogels were then transferred to a tube containing 1 
ml of fresh TDW and the tube was inverted several times to remove any 
kanamycin that had transiently adhered through non-specific interactions. 
Kanamycin loading capacity of the hydrogel was quantified by measuring the 
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fluorescence of fluorescein isothiocyanate (FITC)-conjugated kanamycin after 
dialysis against TDW using a 1000-Da dialysis membrane (Spectra/Por 7 Dialysis 
Membrane; Spectrum Labs, CA, USA).  
In some experiments, fluorescent kanamycin (F-Kan) or fluorescent gentamicin 
(F-Gen) was loaded into GO-PA hydrogels to produce F-Kan-loaded GO-PA 
(F-Kan/GO-PA) or F-Gen-loaded GO-PA (F-Gen/GO-PA) hybrid hydrogels. 
Fluorescent antibiotics were synthesized by mixing 43.44 mg FITC (Sigma Aldrich 
Co.) with 130 mg kanamycin sulfate salt (Duchefa Biochemie, Haarlem, 
Netherlands) or 130 mg gentamicin sulfate salt (Duchefa Biochemie) in a solution 
of 0.5 ml triethylamine and 10 ml dimethyl formamide (both from Sigma-Aldrich 
Co.). The mixture was incubated for 16 h with stirring. Thereafter, the solvent was 
evaporated, and the resulting powder was washed twice with 10 ml methanol and 
then with 10 ml acetone. The purified powder was dried by vacuum evaporation 
and dissolved in TDW to yield F-Kan or F-Gen solutions. In addition to 
quantitative evaluation, drug loading was qualitatively demonstrated by imaging 
hydrogels using the BioRad GelDoc XR system (BioRad, Hercules, CA, USA) in 
Trans-UV mode.  
 
2.8. Antibacterial efficacy of Kan/GO-PA hybrid hydrogels 
The antibacterial effects of Kan/GO-PA hybrid hydrogels against both 
gram-positive and gram-negative bacteria were investigated. Gram-negative 
Enterobacteriaceae (Escherichia coli) and gram-positive Staphylococcus aureus 
were obtained from American Type Culture Collection (Manassas, VA, USA). E. 
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coli was grown in nutrient broth (NB) and S. aureus in trypticase soy broth (TSB) 
medium, as recommended by the supplier. The selected assay method was the 
colony formation assay. Briefly, 100 µl of E. coli or S. aureus, each at an optical 
density at 600 nm (OD600) of 0.3, were diluted with 100 µl of NB and TSB, 
respectively. Kan/GO-PA hydrogels were then incubated in bacterial solutions at 
37°C for 1 h with stirring. Stirring was then halted and solutions were left 
undisturbed for 5 min. Once the hydrogel had settled to the bottom of the tube, 200 
µl of E. coli and S. aureus solutions was inoculated onto NB and TSB agar plates, 
respectively, and incubated overnight at 37°C. The next day, the plates were 
imaged using Epi-white exposure, and the number of colonies on each plate was 
determined using the BioRad GelDoc XR system. 
 
2.9. In vivo imaging of GO-PA hybrid hydrogel 
For in vivo molecular imaging, F-Kan/GO-PA hydrogel (1.8 mg) was injected 
subcutaneously into the right flank of a shaved Balb/c mouse (Orientbio Inc., 
Seongnam, Republic of Korea) using a 1 ml insulin syringe (BD Ultra-fine II 
insulin syringes; Becton Dickinson and Company, Franklin Lakes, NJ, USA). Mice 
were shaved to eliminate interference with fluorescence detection caused by hairs. 
Fluorescence intensity emanating from the injected hydrogel was detected at 
predetermined time points with an Optix molecular imaging system (Advance 
Research Technologies Inc. Montreal, Canada) at a wavelength of 485 nm and an 




3. Results  
 
3.1. Construction of GO-PA hybrid hydrogels  
GO-PA hybrid hydrogels were constructed using a DNA hydrogel matrix with 
GO as crosslinker. As depicted in Figure IV-1, the RCA template was composed of 
a circularizing primer-binding sequence, a GO-binding 12-mer oligo A sequence, 
and 21-mer kanamycin-binding aptamer sequence. The GO-binding 12-mer oligo 
A sequence was introduced to exploit the ssDNA-binding property of GO 
nanosheets. GO nanosheets were added partway through the RCA reaction (30 min 
after RCA initiation) to ensure that the ssDNA produced by RCA would be 
adsorbed onto GO nanosheets concomitant with continuous production of RCA 
products. In the presence of GO nanosheets, RCA scrambled or polyaptamer 
template containing the 12-mer oligo A sequence formed a light brown GO-PA 
hybrid gel after the RCA reaction.  
 
3.2. Characterization of GO-PA hybrid hydrogels  
GO-PA hybrid hydrogels were characterized with respect to morphology, X-ray 
diffraction pattern, swelling behavior, and rheologic properties. The topology of 
GO-PA hydrogels was examined by SEM, which showed that, whereas the surfaces 
of GO nanosheets were relatively smooth (Fig. IV-2), those of GO-PA hybrid 
hydrogels was rough and ruffled (Fig. IV-2B). Notably, an enlarged image of 
GO-PA hybrid hydrogels (Fig. IV-2C) showed pores spread throughout the 







Fig. IV-1. Construction of GO-PA hybrid hydrogels. 
Schematic mechanism of GO-PA hybrid hydrogel formation through a single-step 
RCA reaction. The compositions of RCA templates for kanamycin-specific 
polyaptamer with or without a 12-mer oligo A sequence, or scrambled polyaptamer 


















Fig. IV-2. Morphology of GO-PA hybrid hydrogels. 
SEM images of GO nanosheets alone (A) and GO-PA hybrid hydrogels (B, C, D) 
of different magnifications. Scale bars = 100 nm (A), 2 µm (B), 400 nm (C), and 




GO-PA hybrid hydrogels. The distinctive XRD peak of GO nanosheets at 9.5° 
disappeared in the XRD pattern of GO-PA hybrid hydrogels (Fig. IV-3A). The 
swelling ratio of dried GO-PA hydrogel in TDW increased over time, reaching a 
maximum at 2 h (Fig. IV-3B). The hydrogel was capable of swelling up to 700%, 
whereas the dried RCA product of polyaptamer template containing the 12-mer 
oligo A sequence showed no water uptake. With respect to the dynamic rheological 
behavior, shear storage (G’) values of GO-PA hydrogels were higher than loss 
modulus (G”) values over a range from 0.01 to 10 Hz (Fig. IV-3C).  
 
3.3. Kanamycin-specific loading into GO-PA hydrogels  
The proposed GO-PA hydrogels could specifically entrap kanamycin in the 
hydrogel matrix, as depicted in Figure IV-4A. Estimates of drug loading efficiency, 
determined by monitoring the fluorescence intensity of F-Kan-loaded hydrogels, 
confirmed this. In contrast to GO-SC hydrogels, which showed a 1.5 % F-Kan 
loading efficiency (Fig. IV-4B), GO-PA hydrogels showed a F-Kan loading 
efficiency of 58.0 %—38-fold higher than that of GO-SC hydrogels. Both 
hydrogels were indistinguishable under the naked eye, but under 320 nm UV light, 
only F-Kan/GO-PA hydrogels showed F-Kan fluorescence (Fig. IV-4C). In contrast, 
the loading efficiencies of F-Gen were 1.2 % for GO-SC and 1.3 % for GP-PA 
hydrogels (Fig. IV-4B), and F-Gen/GO-PA hydrogels exhibited little fluorescence 
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Fig. IV-3. Physicochemical characterization of GO-PA hybrid 
hydrogels. 
(A) XRD patterns of plain GO nanosheets and GO-PA hybrid hydrogels. (B) Dried 
RCA products of polyaptamer template with a 12-mer oligo A sequence or GO-PA 
hydrogels were placed in water, and swelling ratios were calculated over time. (C) 
The shear storage modulus, G’, and the shear loss modulus, G”, of the hydrogels 



































Fig. IV-4. Drug-specific loading of GO-PA hydrogels. 
(A) Illustration of drug loading into GO-PA hydrogels. (B) F-Kan or F-Gen loading 
capacity of GO-PA hybrid hydrogels was calculated from the fluorescence of each 
drug compared to that of the GO-SC hydrogel. (C) Fluorescence images of 
hydrogels loaded with F-Kan or F-Gen. Scale bars = 1 cm.  
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3.4 Antibacterial effect of Kan/GO-PA hydrogels 
Kan/GO-PA exerted significant antibacterial activity against gram-negative E. 
coli (Fig. IV-5A, IV-5B) and gram-positive S. aureus (Fig. IV-5A, IV-5C). In 
contrast, GO-PA showed no significant antibacterial activity against gram-negative 
(Fig. IV-5A, IV-5B) or gram-positive (Fig. IV-5A, IV-5C) bacteria compared to 
untreated controls. Survival, measured as colony-forming units (cfu) per plate, was 
113.2-fold lower for E. coli (Fig. IV-5B) and 94.2-fold lower for S. aureus (Fig. 
IV-5C) in the Kan/GO-PA hydrogel-treated group compared to the untreated group.  
 
3.5 GO-PA hydrogel sustainability in vivo 
To examine the applicability of the proposed Kan/GO-PA hydrogels, we 
evaluated their retention at administration sites. To visualize the retention, 
F-Kan/GO-PA hydrogels were used. For comparison, GO-PA hydrogels were 
injected in the same amounts and imaged. Following subcutaneous injection, 





























Fig. IV-5. Antibacterial effects of Kan/GO-PA hybrid hydrogels. 
(A) Colonies of gram-negative E. coli and gram-positive S. aureus after treatment 
with GO-PA or Kan/GO-PA hydrogels. The cfu/plate values for E. coli (B) and S. 





















Fig. IV-6. In vivo retention of hydrogels at injection sites. 
Mice were subcutaneously injected with GO-PA hydrogel or F-Kan/GO-PA 
hydrogel. The molecular images were obtained immediately after hydrogel 





Here, we report an injectable GO-PA hybrid hydrogel for use as a drug-delivery 
system. Drug specificity and loading efficiency were conferred by incorporating a 
kanamycin-specific DNA aptamer sequence into the RCA template, and GO 
binding was provided by including a 12-mer oligo A sequence in the RCA template. 
GO nanosheets acted as a hydrogel crosslinker of RCA products, exploiting the 
ssDNA-binding property of GO nanosheets. Moreover, Kan/GO-PA hydrogels had 
rheological properties suitable for an injectable formulation and were retained at 
the injection site.   
GO-PA hybrid hydrogels were generated using a single-step RCA reaction (Fig. 
IV-1), a reaction made possible by using a 12-mer oligo A as a binder of GO 
nanosheets. Zhang et al. previously reported that GO nanosheets bind to ssDNA, 
but not to double-stranded DNA [12]. Lu et al. [16] also reported that GO 
nanosheets bind fluorescent ssDNA, and quench the fluorescence of ssDNA. But, 
unlike ssDNA, double-stranded DNA was found to be liberated from GO 
nanosheets [16]. Given the unique structure-forming ability of aptamer sequences, 
we expected that the polyaptamer alone might lack sufficient ssDNA regions to 
bind GO. Indeed, this possibility was supported by our demonstration that RCA 
products formed using a polyaptamer template without 12-mer oligo A sequences 
could not form hydrogels in the presence of GO, and instead formed a suspension 
(Fig. IV-1). Using the single-step RCA reaction to produce hydrogels enabled us to 
avoid the use of toxic chemical cross-linkers or inconvenient multistep reaction 
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schemes to produce three-dimensional networks of cross-linked DNA hydrogels.  
GO-PA hybrid hydrogels exhibited a bird’s nest-like surface morphology with 
pores (Fig. IV-2). This morphology is similar to that previously reported for 
RCA-generated DNA hydrogels based on SEM imaging [17]. Given that hydrogels 
are composed of polymers that crosslink to form a three-dimensional network [18], 
porosity is an intrinsic property of a hydrogel. Previous studies of DNA-based 
hydrogel creation methods have used the presence of a porous interior to indicate 
successful generation of a hydrogel [17,19].  
Binding of GO to PA to form hydrogels was further confirmed by XRD 
patterns (Fig. IV-3A). The 2θ peak for freeze-dried GO that appeared at 9.5° 
corresponded to a layer-to-layer stacking distance of 8.34 Å [19]. The 
disappearance of an XRD diffraction peak for freeze-dried GO-PA hydrogels at the 
same angle could reflect the absence of direct interactions or ordered stacking 
between GO nanosheets owing to formation of a three-dimensional structure.  
GO-PA hybrid hydrogels retained the key characteristics of hydrogels, including 
swelling and viscoelasticity. Another distinctive feature of GO-PA hydrogels is the 
700 % swelling through water absorption (Fig. IV-3B). Compared to previously 
reported DNA hydrogels, which showed about 100% swelling in 1 day [7], our 
GO-PA hydrogels showed greater swelling and more rapid swelling kinetics. This 
superb swelling behavior of GO-PA hydrogels is likely attributable to the dense 
network of GO-crosslinked hydrophilic DNA components. 
In addition to porosity and swelling properties, GO-PA hydrogels were found to 
exhibit viscoelasticity (Fig. IV-3C). The shear-storage modulus (G’) represents the 
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elasticity of the hydrogel, whereas the shear-loss modulus (G”) represents viscosity 
[20]. Our observation that G’ was higher than G” over the entire tested range (0.01 
to 10 Hz) indicates that GO-PA formed a solid hydrogel [7]. The values of G’ and 
G” for GO-PA hydrogels fall within the range of injectable hydrogels, regardless of 
materials used to form the hydrogel [21,22]. Moreover, compared to hydrogels 
generated with only RCA-produced DNA, which showed a G’ less than 10 Pa [17], 
the elasticity of GO-PA hydrogels was almost 10-fold higher (~100 Pa) in the 
frequency range of 1 to 10 Hz. These findings imply that the proposed hydrogel 
platform possesses advantageous mechanical properties, which may be attributable 
to the presence of the GO crosslinker.  
We demonstrated drug-specific loading and high loading efficiency of GO-PA 
hydrogels using kanamycin as a model drug (Fig. IV-4). The kanamycin-specific 
loading of GO-PA hydrogels supports the conclusion that GO-PA hydrogels 
retained the target drug-specific aptamer function. The nucleic acid sequence of the 
kanamycin-specific aptamer has been previously reported [15]. Although we used 
kanamycin because of the availability of kanamycin-specific aptamer sequences, 
the hydrogel system could be used for other antibiotics by replacing aptamer 
sequences with other antibiotic-specific aptamer sequences. There are reports of 
DNA aptamers that can recognize and capture other antibiotics, such as 
tetracycline [23] and gentamicin [24]. Therefore, the application of GO-PA hybrid 
hydrogel system to other drugs is only limited by the availability of appropriate 
drug-specific aptamer sequences. Consistent with efficient drug loading, 
Kan/GO-PA hydrogels exerted antibacterial effects, whereas GO-PA hydrogels did 
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not (Fig. IV-5). These observations are consistent with recent reports that GO 
nanosheets alone do not show any antibacterial effects [25-27].  
We found that GO-PA hydrogels could be injected through a fine-gauged 
needle and were retained at the injection site (Fig. IV-6). The retention of hydrogel 
at the injection site is supported by the viscosity of the gel, as evidenced by 
rheology data (Fig. IV-3C). Importantly, the injectability of hydrogels, which 
results from their elastic properties, would enable patients to receive only a bolus 
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Rolling circle amplification (RCA) is an isothermal, enzymatic process 
mediated by unique DNA and RNA polymerases in which long single-stranded  
(ss) DNA molecules are produced on a short circular ssDNA template by using a 
single DNA primer. As RCA products contain repetitive sequences that are 
complementary to the circular DNA template, the DNA products can be 
manipulated to include multifunctional sequences by designing the DNA template. 
These functional RCA-based nanotechnologies have been utilized for various 
biomedical applications including drug delivery.  
For delivery of antisense oligonucleotides (ASOs), we developed biomimetic 
hyaluronic acid (HA)-coated, Mu peptide-condensed, dual ASO-loaded DNA 
nanoballs (HMA nanoballs). RCA technique was used for amplification of 
ASO-binding sequences, and dual ASOs, Dz13 and OGX-427, were incorporated 
onto HMA nanoballs through sequence-specific complementary hybridization. 
Surface coating with HA enhanced CD44 receptor-mediated delivery of HMA 
nanoballs to tumor cells. Importantly, ASOs delivered by HMA nanoballs 
suppressed the expression of their target mRNAs of ASO, exerting potent 
anticancer effects in vitro and in vivo upon co-treatment with doxorubicin (Dox). 
Although DNA aptamers have emerged as a potential targeting moiety for drug 
delivery systems, their binding affinity is generally lower than that of antibodies. 
To overcome the problem, we synthesized tumor cell-specific polyaptamer 
nanothreads by RCA. Reduced graphene oxide (rGO) coated with protein tyrosine 
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kinase 7 (PTK7) polyaptamer nanothreads (PNTrGO) improved cellular uptake 
into PTK7-positive tumor cells lines and enhanced tumor tissue accumulation 
compared to scrambled polyaptamer-anchored rGO nanosheets. Moreover, 
systemic administration of Dox using PNTrGO enhanced the antitumor effects in 
mice bearing PTK7-positive tumors. 
Graphene oxide-crosslinked DNA polyaptamer (GO-PA) hybrid hydrogels 
were constructed by running single RCA of DNA template in the presence of GO 
nanosheet. PA-GO hybrid hydrogels exhibited a bird’s nest-like surface 
morphology, a swelling ratio of 657% at 2 h, and viscoelasticity suitable for 
injection and retention. PA-GO hybrid hydrogels specifically bound Kan, 
exhibiting a drug loading efficiency of 58.0% for Kan compared with 1.5% for 
gentamicin. Kan-loaded PA-GO (Kan/PA-GO) hybrid hydrogels exerted 
antibacterial activity against gram-negative (Escherichia coli) and gram-positive 
(Staphylococcus aureus) bacteria. In mice, subcutaneously injected, fluorescent 
Kan-loaded PA-GO hybrid hydrogel was retained at the injection site.  
In our proof-of-principle study, functional DNA nanostructure by RCA 
technique has been developed. The RCA-based DNA nanostructures were capable 
of delivery of gene, chemical drug, and antibiotics. Overall, these DNA 
















Rolling circle amplification(RCA)을 활용한 나노 전달체 제조기술은 
약물전달 분야에서 신규한 전달체를 개발하기 위한 차세대 기술로서 
각광받고 있다. RCA 반응으로 제조한 DNA nanoball은 antisense 
oligonucleotide(ASO)의 상보적인 서열을 포함하므로 두 가지 이상의 
ASO(Dz13, OGX-427) 의약을 서열 특이적으로 탑재 가능하다. 또한, DNA 
nanoball의 표면에 코팅된 히알루론산에 의해 암세포조직에 과발현하는 
CD44수용체에 특이적으로 ASO 의약을 전달할 수 있다. DNA nanoball에 
의해 세포 내로 전달된 ASO는 타겟 mRNA(HSP27, c-jun)의 발현을 
억제하여 세포와 소동물 수준에서 강력한 항암효과를 보였다. 
RCA 기술을 활용하여 단백질 인산화 효소로 알려진 protein tyrosine 
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kinase 7(PTK7)에 특이적으로 결합 가능한 DNA polyaptamer nanothread를 
합성하였다. DNA polyaptamer nanothread를 합성할 때 사용되는 DNA 
template에는 bridge 서열을 포함시켜 환원 그래핀 나노시트(rGO)와의 
interaction을 향상시키고자 하였다. 합성된 DNA polyaptamer 
nanothread를 환원그래핀 나노시트(PNTrGO)의 표면에 부착한 결과, 
표적능이 없는 DNA polyaptamer nanothread을 부착한 환원그래핀 
나노시트(SNTrGO)와 비교하였을 때, 표적 PTK7 단백질이 과발현하는 암 
세포주 및 암 조직에서 향상된 세포전달능력 및 축적능력을 확인하였다. 
더 나아가 항암의약 독소루비신(doxorubicin)을 탑재한 후 표적 PTK7 
단백질을 과발현하는 암 동물모델에 전신투여 하였을 때 항암효과가 
있음을 확인하였다.  
항생제 약물에 특이적으로 결합 가능한 DNA polyaptamer를 
RCA반응으로 제조하고 여기에 crosslinker 역할을 할 수 있는 그래핀 
나노시트를 첨가하여 주입형 하이드로겔을 개발하였다. GO-PA 
하이브리드 하이드로겔은 특이적으로 항생제 카나마이신을 탑재할 수 
있다. GO-PA 하이브리드 하이드로겔에 카나마이신과 젠타마이신을 
탑재하여 약물 특이적 loading 효율을 비교한 결과, 카나마이신은 58.0%, 
젠타마이신은 1.2%의 탑재효율을 보였다.  
주요어: DNA nanoball, rolling circle replication, drug delivery, aptamer, 
graphene nanosheet, reduced graphene nanosheet 
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